WO2016209555A1 - Ophthalmic formulations of tyrosine kinase inhibitors, methods of use thereof, and preparation methods thereof - Google Patents

Ophthalmic formulations of tyrosine kinase inhibitors, methods of use thereof, and preparation methods thereof Download PDF

Info

Publication number
WO2016209555A1
WO2016209555A1 PCT/US2016/034822 US2016034822W WO2016209555A1 WO 2016209555 A1 WO2016209555 A1 WO 2016209555A1 US 2016034822 W US2016034822 W US 2016034822W WO 2016209555 A1 WO2016209555 A1 WO 2016209555A1
Authority
WO
WIPO (PCT)
Prior art keywords
ophthalmic formulation
pharmaceutically acceptable
nintedanib
ophthalmic
tyrosine kinase
Prior art date
Application number
PCT/US2016/034822
Other languages
French (fr)
Inventor
Tan Nguyen
Chin-yu LAI
Original Assignee
Allgenesis Biotherapeutics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU2016283517A priority Critical patent/AU2016283517B2/en
Application filed by Allgenesis Biotherapeutics Inc. filed Critical Allgenesis Biotherapeutics Inc.
Priority to MX2017016655A priority patent/MX2017016655A/en
Priority to KR1020177034479A priority patent/KR20170140399A/en
Priority to EP16814997.9A priority patent/EP3310339A4/en
Priority to BR112017025757-2A priority patent/BR112017025757B1/en
Priority to KR1020207003834A priority patent/KR102096296B1/en
Priority to CA2989121A priority patent/CA2989121C/en
Priority to CN201680029483.5A priority patent/CN107708664B/en
Priority to JP2017566347A priority patent/JP6680807B2/en
Publication of WO2016209555A1 publication Critical patent/WO2016209555A1/en
Priority to US15/700,735 priority patent/US10154994B2/en
Priority to US15/964,235 priority patent/US11369600B2/en
Priority to US17/750,400 priority patent/US20220280506A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the invention relates to ophthalmic formulations comprising tyrosine kinase inhibitors, such as Nintedanib, Axitinib, and Sorafenib, and the use of such ophthalmic
  • Ophthalmic medication is usually applied to the eye to treat the outside of the eye, as well as to provide intraocular treatment through the cornea.
  • most ocular diseases are treated by topical drug application in the form of solutions, suspensions, and gels.
  • a topical drug delivery system for ophthalmic uses should possess certain desirable properties, such as good corneal and conjunctival penetration of the active drug, prolonged pre-corneal residence time, easy instillation, non-irritating, and comfortable to minimize lachrymation and reflex blinking. It should also have appropriate rheological properties.
  • neovascularization and disorders related to vascular permeability are often poorly soluble in water.
  • Conventional approaches often attempt to solubilize insoluble drugs with the use of high concentrations of co-solvents, but this poses problems of toxicity and ocular tolerability.
  • the formulation for ophthalmological applications should be capable of being easily administered without causing eye irritation, thus increasing patient compliance.
  • the formulation should also deliver an active agent to the eye at a concentration which is sufficient for effective therapy.
  • the invention satisfies this need by providing novel ophthalm ic formulations that are efficacious in treating ocular diseases, particularly ocular surface diseases, such as pterygium.
  • novel ophthalm ic formulations that are efficacious in treating ocular diseases, particularly ocular surface diseases, such as pterygium.
  • the ophthalmic formulations of the invention can be administered topically, are well tolerated, and have little to no toxicity.
  • the invention relates to an ophthalmic formulation comprising a therapeutically effective amount of Nintedanib, a prodrug thereof, or a
  • the ophthalmic formulation comprises
  • the ophthalmic formulation comprises Nintedanib Ethanesulfonate.
  • the ophthalmic formulation further comprises tyloxapol as a surfactant.
  • the ophthalmic formulation is a liquid suspension.
  • the ophthalmic formulation is a topical ocular composition.
  • the ophthalmic formulation comprises a therapeutically effective amount of micronized or nanonized particles of a tyrosine kinase inhibitor selected from the group consisting of Axitinib, Nintedanib, Sorafenib, Pazopanib, a pharmaceutical ly acceptable prodrug thereof, and a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.
  • a tyrosine kinase inhibitor selected from the group consisting of Axitinib, Nintedanib, Sorafenib, Pazopanib, a pharmaceutical ly acceptable prodrug thereof, and a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.
  • the ophthalm ic formulation comprises nanonized particles of Nintedanib or a pharmaceutically acceptable salt thereof.
  • the invention in another general aspect, relates to a method of treating an ocular surface disease in a subject in need thereof, the method comprising administering to an eye of the subject an ophthalmic formulation of the invention.
  • the ocular surface disease is hyperemia associated with pterygium, pterygium conj unctivae, or recurrent pterygium.
  • adminstration of the ophthalmic formulation is topical ocular administration.
  • the invention relates to a method of preparing an ophthalmic formulation of the invention, comprising combining a tyrosine kinase inhibitor selected from the group consisting of Axitinib, Nintedanib, Sorafenib, Pazopanib, a
  • the method further comprises form ing microparticles or nanoparticles of the tyrosine kinase inhibitor for inclusion in the ophthalmic formulation of the invention.
  • the invention also relates to use of an ophthalmic formulation of the invention in the preparation of a medicament for treating an ocular surface disease.
  • Figures 1 A and I B show representative photographic images of corneal neovascularization in a New Zealand white rabbit model of cornea suture-induced
  • FIG. 1 A shows m.l neovascularization on day 7
  • Figure I B shows neovascularization of the cornea on day 14 with the arrow pointing to the area of neovascularization
  • Figures 2A and 2B show representative photographic images of corneal
  • FIG. 2A and 2B show little to no neovascularization of the cornea on clay 7 and 14, respectively; the arrow in Figure 2B points to the area of the eye in which any neovascularization would be expected to be observed;
  • Figures 3A and 3B show representative photographic images of corneal
  • Figure 3 A and 3B show no neovascularization of the cornea on day 7 and 14, respectively;
  • Figures 4A and 4B show representative photographic images of corneal
  • Figures 5A and 5B show representative photographic images of corneal
  • Figure 5A and 5B show little neovascularization of the cornea on day 7 and 14, respectively, with the arrow pointing to the area of neovascularization;
  • Figure 6 is a distribution diagram that shows the effect of different surfactants on the size distribution of Nintedanib particle.
  • phrases "pharmaceutically acceptable salt” as used herein means those salts of a compound of interest that are safe and effective for administration to a mammal and that possess the desired biological activity.
  • Pharmaceutically acceptable acid salts include, but are not limited to hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, carbonate, bicarbonate, acetate, lactate, salicylate, citrate, tartrate, propionate, butyrate, pyruvate, oxalate, malonate, pantothenate, bitartarte, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, /?-toIuenesulf
  • Suitable base salts include, but are not limited to, aluminum, calcium, lithium, magnesium, potassium, sodium, zinc, bismuth, and diethanolamine salts.
  • Suitable base salts see Berge et al. , J. Pharm. Sci. ( 1977) 66, 1 - 1 9, incorporated herein by reference.
  • the invention relates to ophthalmic formulations and methods of using the ophthalmic formulations to treat ocular surface disorders.
  • An "ophthalmic formulation" as used herein refers to any pharmaceutical composition suitable for ocular administration, i.e., administration to the eye.
  • the ophthalmic formulation is suitable for topical administration to the eye, although the ophthalmic formulation can be formulated as a
  • ophthalmic formulations suitable for topical administration can be in the form of a liquid, such as a suspension or a solution; cream; ointment; gel; gel-forming liquid; suspension containing liposomes or micelles; spray formulation; emulsion; erodible or non-erodible carriers that can be inserted into the cul-de-sac of the eye.
  • the ophthalmic formulation is a liquid suspension.
  • an ophthalmic formulation comprises a therapeutically effective amount of a tyrosine kinase inhibitor.
  • therapeutically e ffective amount means an amount of a therapeutically active compound needed to elicit the desired biological or clinical effect.
  • a therapeutically active compound needed to elicit the desired biological or clinical effect.
  • tyrosine kinase inhibitor refers to a therapeutically active compound that is capable of inhibiting the activity of one or more tyrosine kinases, such as, for example, platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptor (FGFR), vascular endothelial growth factor receptor (VEGFR), and Fms-like tyrosine kinase-3 (FLT3).
  • PDGFR platelet-derived growth factor receptor
  • FGFR fibroblast growth factor receptor
  • VEGFR vascular endothelial growth factor receptor
  • FLT3 Fms-like tyrosine kinase-3
  • tyrosine kinase inhibitors suitable for use with the invention include, but are not limited to, Nintedanib, Sorafenib, Axitinib, Pazopanib, pharmaceutically acceptable prodrugs thereof, and pharmaceutically acceptable salts thereof.
  • the tyrosine kinase inhibitor is Nintedanib or Axitinib, and more preferably is Nintedanib.
  • Preferred pharmaceutically acceptable salts of Nintedanib include Nintedanib ethanesulfonate.
  • Nintedanib, Sorafenib, Axitinib, and Pazopanib have the following formula (I) (II), (III), and (IV) respectively:
  • prodrugs of the above mentioned tyrosine kinase inhibitors are also contemplated herein.
  • the term "prodrug” as used herein means a compound that is converted in vivo to yield a compound of Formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof.
  • a prodrug is typically a drug precursor that is converted in vivo to a biologically active compound or drug.
  • the in vivo conversion can occur by various mechanisms, including metabolic and/or chemical processes, such as, for example, through hydrolysis in the blood or target tissue, such as the eyes (see, e.g., Rautio et al., Nature Reviews 7, 255-270 (2008)).
  • a prodrug in accordance with embodiments of the invention, if a compound of Formula (1), (II), (III), or (IV) incorporates an amine functional group, a prodrug can be formed by replacing a hydrogen atom of the amine, urea or amide group with a functional group such as, for example, -C(0)R or -C(0)OR; or a prodrug can be formed by replacing one or two hydrogen atom(s) of a sulfonamide group with one to two functional group(s), such as -C(0)R or-RR', wherein R and R' are each independently (Ci -Cio)alkyl, (C 3 - C 7 )cycIoalkyI, or benzyl.
  • -C(0)R can be a natural a-aminoacyl or - C(OH)C(0)OY' , wherein Y 1 is H, (C C 6 )alkyl, benzyl, or -C(OY 2 )Y 3 ; Y 2 is (C, -C 4 )alkyl; Y 3 is (C, -C 6 )alkyl, carboxy(Ci-C 6 )alkyl, amino(Ci-C 4 )alkyl, mono-N- or di-N, N-(C r
  • tyrosine kinases FGFR, PDGFR, and VEGFR have been implicated in idiopathothic pulmonary fibrosis.
  • Nintedanib Ethanesulfonate was previously approved for the treatment of idiopathic pulmonary fibrosis, as well as for treating locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) in combination with docetaxel.
  • NSCLC non-small cell lung cancer
  • the tyrosine kinase inhibitor is Nintedanib, a prodrug thereof, or a pharmaceutically acceptable salt thereof, such as Nintedanib Ethanesulfonate.
  • the tyrosine kinase inhibitor is Axitinib, a prodrug thereof, or a pharmaceutically acceptable salt thereof.
  • the tyrosine kinase inhibitor is Sorafenib, a prodrug thereof, or a pharmaceutically acceptable salt thereof.
  • the tyrosine kinase inhibitor is Pazopanib, a pharmaceutically acceptable salt thereof, or a prodrug thereof.
  • an ophthalmic formulation comprises at least one pharmaceutically acceptable excipient.
  • pharmaceutically acceptable excipients include, but are not limited to, surfactants, preservatives, viscosity regulators, pH-active components (e.g., pH-adjusting agents, buffering agents etc.), stabilizers, and osmo-regulators (tonicity adjusters).
  • Suitable surfactants that can be used in an ophthalmic formulation according to the invention include, but are not limited to, non-ionic surfactants such as poloxamers,
  • polyoxyethylene fatty acid glycerides and oils polyoxyethylene alkyl ethers, polyoxyethylene fatty acid esters, sorbitan esters, polyoxyethylene sorbitan esters, propylene glycol fatty acid esters, fatty acids, glyceryl fatty acid esters, a-tocopheryl polyethylene glycol succinate (TPGS), polyethoxy alkylaryl ether polymers, polymers of alkyl aryl polyether alcohol and the like.
  • TPGS polyoxycopheryl polyethylene glycol succinate
  • the surfactant is Tween 80, Tween 20, poloxamer 1 88, poloxamer 407 or tyloxapol.
  • an ophthalmic formulation further comprises tyloxapol as a surfactant.
  • Suitable viscosity regulators that can be used in an ophthalmic formulation according to the invention include, but are not limited to, hydroxypropyl methylcellulose (HPMC), hydroxypropylcellulose (HPC), carboxymethylcellulose (CMC), methylcellulose (MC), hydroxyethylcellulose (HEC), cellulose and derivatives thereof, polycarbophil, polyoxyethylene glycol (PEG), hyaluronic acid (HA), amylase and derivatives thereof, amylopectins and derivatives thereof, dextran and derivatives thereof, polyvinylpyrrolidone (PVP), polyvinyl alcohol (PVA), and acrylic polymers such as derivatives of polyacrylic or polymethacrylic acid including hydroxylmethyl methacrylate (HEMA), carbomer or a mixture thereof.
  • HPMC hydroxypropyl methylcellulose
  • HPC carboxymethylcellulose
  • MC methylcellulose
  • HEC hydroxyethylcellulose
  • cellulose and derivatives thereof polycarbophil, polyoxyethylene
  • the viscosity regulator is selected from the group consisting of HPMC, sodium carboxymethylcellulose, carbomer, polycarbophil, PEG, and HA.
  • the viscosity regulator is HPMC.
  • Suitable pH active components such as buffering agents or pH-adjusting agents, that can be used in an ophthalmic formulation according to the invention include, but are not limited to, acids, such as boric acid, citric acid, hydrochloric acid, and salts thereof; and alkali metal salts, such as disodium phosphate, monosodium phosphate, sodium borate, sodium citrate, sodium hydroxide, and potassium phosphates.
  • the pH of an ophthalmic formulation can vary from about 5.0 to 8.0, such as 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, or 8.0.
  • the pH is between about 6.0 and 7.5.
  • the pH can be adjusted to control the particle size distribution of the tyrosine kinase inhibitor in the ophthalmic formulation.
  • the pH can also be adjusted to provide for optimal chemical stability of the active ingredient.
  • the tonicity of an ophthalmic formulation is isotonic, or slightly hypotonic as compared to tears, in order to combat any hypertonicity of tears caused by evaporation and/or disease.
  • the osmolality of an isotonic or slightly hypotonic ophthalmic formulation of the invention can be about 250-300 milliosmoles per kilogram (mOsm/kg).
  • a tonicity adjustor can be used to bring the osmolality of the formulation to a level at or near 250-350 mOsm/kg.
  • Suitable tonicity adjusters that can be used include, but are not limited to, ionic and nonionic osmotic adjusting agents such as sodium chloride, potassium chloride, dextran, cyclodextrins, mannitol, dextrose, glycerol, sorbitol, boric acid, borax and propylene glycol and combinations thereof.
  • ionic and nonionic osmotic adjusting agents such as sodium chloride, potassium chloride, dextran, cyclodextrins, mannitol, dextrose, glycerol, sorbitol, boric acid, borax and propylene glycol and combinations thereof.
  • Preservatives that can be used in an ophthalmic formulation according to the invention include, but are not limited to, benzalkonium chloride, cetrimide, cetylpyridinium chloride, benzododecinium bromide, benzethonium chloride, thiomersal, chlorobutanol, benzyl alcohol, phenoxyethanol, phenylethyl alcohol, sorbic acid, methyl and propyl parabens, chlorhexidine digluconate, EDTA, polyquad, purite, perborate-based preservatives, other mercuric compounds, zinc polyol complexes, or mixtures thereof.
  • benzalkonium chloride is included in the ophthalmic formulation as a preservative.
  • the benzalkonium chloride is preferably present in an amount from about 0.001 to 0.02% w/v, such as 0.001 %, 0.005%, 0.01 %, or 0.02%, and most preferably about 0.005% w/v.
  • a concentration of the tyrosine kinase inhibitor in an ophthalmic formu lation ranges from about 0.0 1 % to about 1 0% w/v, such as 0.01 %, 0.03%, 0.05%, 0.1 %, 0.3%, 0.5%, 1 %, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, or 10%.
  • a "particle of a tyrosine kinase inhibitor” refers to a particle comprising the tyrosine kinase inhibitor.
  • a “particle” as used herein can be a droplet, vesicle, a lipsome, a micelle, etc.
  • a particle of a tyrosine kinase inhibitor can optionally comprise other ingredients, such as phosphochol ine, fatty acid glycerides, PLGA and PLA.
  • an ophthalm ic formulation comprises "micronized,” preferably “nanonized,” particles that comprise a tyrosine kinase inhibitor, such as nanonized or micronized particles of Nintedanib, Sorafenib, Axitinib, or Pazopanib.
  • nano-sized particle As used herein, the terms “nanonized particle,” “nano-sized particle,”
  • nanoparticle and “sub-micron particle” all refer to a particle comprising a therapeutically active compound having an average particle diameter that is in the sub-micron range, and ranges from about 1 nanometer (nm) to less than about 1 000 nm, preferably 1 00 nm to 900 nm, and more preferably about 200 nm to about 800 nm.
  • nanometer refers to a process of reducing the particle size, i.e., the average diameter of the particle, into the nanometer range.
  • micronized particle As used herein, the terms “micronized particle,” “micro-sized particle,” and
  • microparticle all refer to a particle comprising a therapeutically active compound having an average particle diameter that ranges from about 0.5 ⁇ to about 1000 ⁇ , preferably about 0.5 ⁇ to about 1 00 ⁇ , and more preferably about 0.5 ⁇ to about 10 ⁇ .
  • the term “micronize” refers to a process of reducing the particle size, i.e., the average diameter of the particle, down to a few microns, such as in the range of about 1 ⁇ to about 1 0 ⁇ .
  • an ophthalmic formulation is a liquid suspension.
  • the liquid suspension is preferably suitable for topical administration.
  • the liquid suspension can be a "nanosuspension" or a "microsuspension.”
  • a “nanosuspension” as used herein refers to a suspension comprising particles of a tyrosine kinase inhibitor with at least a majority of the particles in the suspension as nanoparticles having an average particle diameter of less than about 1 ⁇ .
  • a nanosuspension can also have a few particles in the suspension having an average particle diameter greater than about 1 ⁇ .
  • the D90 particle size is about 1 ⁇ or less than 1 .5 ⁇ , and the D50 particle size is less than ⁇ ⁇ .
  • the D90 particle size of a liquid suspension is the diameter at which 90% by volume of the particles in the suspension are smaller in their longest dimension, as measured by any conventional particle size measuring technique known to those skilled in the art.
  • the D 5 o particle size of a liquid suspension is the diameter at which 50% by volume of the particles in the suspension are smaller in their longest dimension, as measured by any
  • the D 50 particle size is therefore a measure of volume median particle size, but is sometimes referred to as
  • particle size '"average or "mean” particle size.
  • Techniques for determining particle size include, but are not limited to, sedimentation field flow fractionation, photon correlation spectroscopy, laser light scattering, and disk centrifugation.
  • a "microsuspension” as used herein refers to a suspension comprising particles of a tyrosine kinase inhibitor with at least a majority of the particles in the suspension as
  • microparticles having an average particle diameter of about 1 ⁇ to 1000 ⁇ .
  • a microsuspension can also have a few particles in the suspension having an average particle diameter less than about 1 ⁇ .
  • the D90 particle size is about less than 20 ⁇ , and the D50 particle size is about less than 10 ⁇ .
  • an ophthalmic formulation comprises nanoparticles or microparticles comprising Nintedanib, or a prodrug thereof, or a
  • an ophthalmic formulation comprises nanoparticles or microparticles comprising Axitinib, or a prodrug thereof, or a pharmaceutically acceptable salt thereof.
  • an ophthalmic formulation comprises nanoparticles or microparticles comprising Sorafenib, or a prodrug thereof, or a pharmaceuticall acceptable salt thereof.
  • an ophthalmic formulation comprises nanoparticles or microparticles comprising Pazopanib, or a prodrug thereof, or a pharmaceutically acceptable salt thereof.
  • an ophthalmic formulation comprises nanoparticles comprising a tyrosine kinase inhibitor having a D 0 particle size of less than 1 ⁇ .
  • Liquid medium can be used in preparing solutions, suspensions and emulsions as ophthalmic formulations of the invention.
  • the tyrosine kinase inhibitor or nanoparticles thereof described herein can be suspended in a pharmaceutically acceptable liquid medium such as water, an organic solvent, a mixture of water and one or more organic solvents, or pharmaceutically acceptable oils or fats.
  • the liquid medium can contain other suitable pharmaceutical additives including, but not limited to, surfactants, preservatives, viscosity regulators, pH-adj listing agents, stabilizers, and osmo-regulators known to those skilled in the art in view of the present disclosure.
  • Micronized or nanonized particles comprising a tyrosine kinase inhibitor for use in the ophthalmic formulation of the invention can be made using any technique known to those skilled in the art in view of the present disclosure.
  • techniques for producing m icronized or nanonized particles include, but are not limited to, milling, homogenization, precipitation, freezing, template emulsion techniques, liposome formation, emulsion,
  • m icroemulsion method solvent extraction/evaporation methods, supercritical fluid technology, spray drying, ultrasonic technology, or any combination thereof.
  • homogenization and milling processes can be combined with a precipitation step in order to achieve smaller particles of narrower size distribution.
  • microparticles or nanoparticles comprising a tyrosine kinase inhibitor are made by dry or wet milling.
  • mills commonly used involve dry-type m ills, such as jet mil l, conventional and planetary bal l mill, vibrational rod m il l, and hammer and knife mill. These dry-type mills are used to grind a drug alone to afford particles of several microns in diameter. However, it is difficult to obtain finer particles, particularly submicron particles of less than 1 ⁇ in diameter, using conventional dry m illing methods.
  • a wet milling may be useful to further reduce particle size (see, e.g., (Lachman et al., "The Theory and Practice of Industrial Pharmacy,” Milling, 45 ( 1986)).
  • media mills such as planetary ball and bead mills which use balls or beads as the grinding media, respectively
  • medialess m i lls such as a high-pressure homogenizer
  • a typical wet milling process comprises dispersing a compound in a liquid dispersion medium in which the compound is poorly soluble, followed by applying mechanical means in the presence of grinding media to obtain a dispersion in which the particle size of the compound is reduced to the desired average particle diameter.
  • the dispersion medium can be, for example, water, safflower oil, ethanol, t-butanol, glycerin, polyethylene glycol (PEG), hexane, or glycol.
  • the particle size of the compound can also be reduced by milling in the presence of at least one surface stabilizer.
  • the compound can be contacted with one or more surface stabil izers after attrition.
  • Other components such as a diluent, can be added to a composition containing the compound and surface stabilizer during the size reduction process.
  • Dispersions can be manufactured continuously or in a batch mode.
  • the mechan ical means appl ied to reduce the particle size during the milling process can take the form of a dispersion mill.
  • Suitable dispersion m ills include a ball mill, an attrition mill, a vibratory mill, and media mills such as a sand mill and a bead mill.
  • a media m i l l is used due to the relatively shorter m i lling time required to provide the desired reduction in particle size.
  • the apparent viscosity of a mixture prior to milling is preferably between 1 00 to about 1 000 centipoise.
  • the apparent viscosity of a mixture prior to milling is preferably between 1 to about 1 00 centipoise. Such ranges tend to afford an optimal balance between efficient particle size reduction and media erosion, but are in no way l imiting. Any other mechanical means known to those skilled in the art in view of the present disclosure can be used to reduce the particle size.
  • the grinding media is selected from rigid media, preferably spherical or particulate in form, and ranging in size from about 0.01 mm to 3 mm, and more preferably 0.01 mm to less than 1 mm.
  • the grinding media is preferably from 0.02 to 2 mm, and more preferably from 0.03 to 1 mm in size.
  • Such grinding media can provide particles for use in the invention with shorter processing times and impart less wear to the mi lling equipment, which are desirable advantages.
  • Non-limiting examples of grinding material include zirconium oxide, such as 95% ZrO stabilized with magnesium ; zirconium silicate; ceramic; stainless steel; titanium; aluminum; yttrium; and glass.
  • the grinding media can contain particles that are preferably spherical in shape, e.g., beads, made of polymeric resin, glass, zirconium silicate, or other suitable material.
  • the grinding media can comprise a core having a coating of a polymeric resin adhered thereon.
  • the grinding media can be separated from milled nanoparticles using conventional separation techniques in a secondary process such as by simple filtration, sieving through a mesh filter or screen, and the like. Other separation techniques, such as centrifugation can also be employed. Alternatively, a screen can be utilized during the milling process to remove the grinding media following completion of particle size reduction.
  • precipitation can be used to form nanoparticles of a tyrosine kinase inhibitor suitable for use in the ophthalmic formulations of the invention.
  • Precipitation includes nanoprecipitation.
  • nanoprecipitation is the nucleation of small aggregates of macromolecules followed by aggregation of these nuclei.
  • Nanomorph is a process by which molecules with low aqueous solubility are converted from a crystalline state into amorphous nanoparticles at the industrial scale by dissolving the tyrosine kinase inhibitor in a solvent, and feeding into a mixing chamber to rapidly mix with a non-solvent for the active pharmaceutical ingredient (API) (i.e., solvent in which the API is not very soluble, or does not dissolve well in).
  • API active pharmaceutical ingredient
  • Another nanoprecipitation approach involves the use of the MicroJet Reactor technology, by which organic solutions of the tyrosine kinase inhibitor and one or more polymers, such as HPMC, sodium carboxymethylcellulose, carbomer, polycarbophil, PEG, and HA collide with a non-solvent for the API in the middle of a gas-filled chamber.
  • the small diameter combined with a high velocity of the jets result in a very fast and intensive mixing and precipitation of insoluble reaction products.
  • the influx of gas carries the dispersion out of the reaction chamber.
  • particle size and size distribution depend on desolvation velocity and precipitation kinetics of polymer(s) and compound, small particles with narrow size distribution can be achieved by this method.
  • Template emulsion creates nanostructured particles with controlled particle size distribution and rapid dissolution performance.
  • Template emulsion involves preparing an oil-in-water emulsion, then swelling in a non-aqueous solution comprising the selected tyrosine kinase inhibitor and stabilizer. The solvent and water are then removed.
  • the resulting particle size distribution of the tyrosine kinase inhibitor is usually based on the size of the emulsion droplets prior to loading with the tyrosine kinase inhibitor, and optimizing the size of the emulsion droplets can be used to control the particle size distribution of the tyrosine kinase inhibitor. Furthermore, through selected use of solvents and stabilizers, emulsion stability is achieved with no or suppressed Oswald ripening. By controlling the processing conditions, such as the size of emulsion droplets, solvents, and stabilizers, various particle morphologies can be achieved.
  • An exemplary homogenization method i.e., forming a suspension comprising nanoparticles or microparticles, and more preferably a suspension comprising nanoparticles. comprises dispersing particles of a tyrosine kinase inhibitor, a prodrug thereof, or a pharmaceutically acceptable salt thereof, in a liquid dispersion medium, followed by
  • a pre-suspension of the particles of tyrosine kinase inhibitor having a particle size in the micrometer range passes through a very small homogenizer gap.
  • the homogenization pressure and number of homogenization cycles are important parameters in optimizing the process, and one of ordinary skill in the art would be able to determine the optimum values for such parameters in order to achieve the desired results.
  • an ophthalmic formulation comprises particles of a tyrosine kinase inhibitor, or a prodrug thereof, or pharmaceutically acceptable salt thereof dispersed in a composition containing a bioadhesive material.
  • a bioadhesive material can be a cationic bioadhesive or an anionic bioadhesive.
  • Particles of the tyrosine kinase inhibitor such as microparticles or nanoparticles, and preferably nanoparticles of the tyrosine kinase inhibitor, can be contacted with a solution comprising a bioadhesive that associates with and/or coats the particles.
  • particles having one or more coatings of the bioadhesive can be formed by layer-by-layer methods.
  • a hollow matrix can first be assembled from the bioadhesive in the solution before the tyrosine kinase inhibitor is encapsulated to form the particle.
  • the bioadhesive coating can be further stabilized by the addition of an oppositely charged polymer, which forms a firm electrostatic complex with the bioadhesive coating. This results in the appearance of a very thin, but stable layer or shell around each nanoparticle. This shell can prevent particle agglomeration, and can be easily and reproducibly formed on the surface of the nanoparticle.
  • a particle coated with the bioadhesive as described herein can have any suitable shape and/or size.
  • a coated particle has a shape substantially similar to the shape of the core.
  • the coated particle described herein can be a nanoparticle or a microparticle.
  • the particles of the tyrosine kinase inhibitor described herein, such as nanoparticles or microparticles can further comprise surface-altering moieties and/or agents that affect the zeta-potential of the particle.
  • surface-altering moieties and/or agents that can be employed in the invention include, but are not limited to, Hyaluronic acid, Carbomer, Polycarbophil, CMC-Na, Benzalkonium chloride, Cetalkonium chloride, Benzethonium chloride, Chitosan, Oleylamine, and Cetrimide.
  • the zeta potential of a coated particle can be, for example, at least about - l OOmV, at least about -75m V, at least about - 50m V, at least about -30mV, at least about -20m V, at least about - l OmV, at least about -5mV, at least about 5mV, at least about l OmV, at least about 20m V, at least about 30m V, at least about 50m V, at least about 75mV, or at least about l OOmV.
  • the coated particle has a zeta potential in a range of about -30m V to 30m V, which is an optimal range of zeta potential for maintaining suspension stability. However, other ranges are also possible.
  • a bioadhesive offers advantages such as localizing a dosage form within a particular region, increasing drug bioavailability, promoting contact with a surface for a longer time, and reducing dosage frequency.
  • the bioadhesive can be biodegradable and/or biocompatible polymers which include, but are not limited to, hyaluronic acid (HA), derivatives of HA and salts of HA, such as cross-linked hyaluronic acid, sodium hyaluronate, and cationic derivative of HA; gelatin, chondroitin sulfate, collagen, cross-linked collagen, collagen derivatives (such as succinylated collagen or methylated collagen), chitosan, chitosan derivatives (such as methylpyrrolidone-chitosan), chitin and other glycosaminoglycans, stearylamine, oleylamine, polyethylenimine (PEI), poly-
  • the invention also relates to use of the ophthalmic formulations described herein to treat or prevent ocular disorders, and particularly ocular surface diseases.
  • a method of treating an ocular surface disease in a subject in need thereof comprises administering to an eye of the subject an ophthalmic formulation of the invention. Any of the ophthalmic formulations described herein can be used in a method of the invention. Preferably, an ophthalmic formulation of the invention is topically administered to the eye of the subject. It is believed that ophthalmic formulations of the invention have advantageous properties in terms of drug release, bioavailability, and/or compl iance in mammals that make them suitable for use in treating ocular disorders, such as ocular surface diseases.
  • subject means any animal, preferably a mammal, most preferably a human, to whom will be or has been treated by a method according to an embodiment of the invention.
  • mammal encompasses any mammal. Examples of mammals include, but are not limited to, cows, horses, sheep, pigs, cats, dogs, mice, rats, rabbits, guinea pigs, non-human primates (NHPs) such as monkeys or apes, humans, etc.. and more preferably a human.
  • An "ocular surface disease” as used herein refers to any disorder of the surface of the eye, which is the exposed layer that forms the front of the eye.
  • ocular surface diseases examples include, but are not limited to, angiogenesis in the front of the eye, such as corneal angiogenesis following e.g. keratitis, corneal transplantation, or keratoplasty; conj unctival degeneration (pinguecula) with slow proliferation; conjunctival papilloma, corneal angiogenesis due to hypoxia; hyperemia; hyperemia associated with pterygium; hyperthyroidism-induced eye congestion; immune or surgery related dry eyes; neovascular glaucoma (NVG); ocular cancer, pterygium conjunctivae; recurrent pterygium;
  • angiogenesis in the front of the eye such as corneal angiogenesis following e.g. keratitis, corneal transplantation, or keratoplasty; conj unctival degeneration (pinguecula) with slow proliferation; conjunctival papilloma, corneal angiogenesis due to hypoxia; hyperemia; hyperemia associated
  • the ocular surface disease to be treated is hyperemia associated with pterygium, pterygium conjunctivae, recurrent pterygium, or corneal angiogenesis.
  • Ptergyium is a condition of the eye characterized by a vascular, pink, fleshy growth on the white of the eye originating from the conjunctiva, which can spread into the corneal limbus.
  • the lesion can take any shape, but is typically triangular or wing-shaped.
  • a pterygium lesion usually has three parts: a cap, a head, and a body/tail.
  • the cap is a flat zone on the cornea containing mostly fibroblasts; the head is a vascular area behind the cap that is firm ly attached to the cornea; and the body/tail is the mobile area over the bulbar conjunctiva. Patients are typically asymptomatic until the lesion spreads into the cornea, where it can cause blurred vision.
  • Pterygium lesions can be primary lesions, or recurrent lesions.
  • Recurrent lesions are lesions that return after removal of the initial primary lesion, such as by surgical removal.
  • Recurrent pterygium refers to pterygium lesions that occur after an initial or primary lesion has already been removed or treated.
  • Pterygium can also be associated with other conditions and side effects, such as hyperemia.
  • Hyperemia redness
  • Hyperemia generally refers to an increase in blood flow to the eye resulting in increased redness of the eye. Hyperemia can occur on its own (primary), or it can be a symptom associated with one or more other ocular diseases (secondary), such as pterygium.
  • ocular diseases characterized by neovascularization, vascular permeability, edema, or inflammation.
  • ocular diseases include but are not limited to ocular inflammation and/or ocular angiogenesis such as aged-related macular degeneration (AMD), proliferative and non-proliferative diabetic retinopathy, choroidal neovascularization, uveitis, rubeosis iridis, and neovascular glaucoma.
  • AMD aged-related macular degeneration
  • proliferative and non-proliferative diabetic retinopathy choroidal neovascularization
  • uveitis rubeosis iridis
  • rubeosis iridis rubeosis iridis
  • treat refers to administering a composition to a subject to achieve a desired therapeutic or clinical outcome in the subject.
  • the terms “treat,” “treating,” and “treatment” refer to administering an ophthalmic formulation of the invention to reduce, alleviate or slow the progression or
  • the terms “treat,” “treating,” and “treatment” refer to administering an ophthalmic formulation of the invention to inhibit or reduce corneal neovascularization and/or cell proliferation in the eye. In yet another embodiment, the terms “treat,” “treating,” and “treatment” refer to administering an ophthalmic formulation of the invention to slow the progression or development of new blood vessels in the cornea (i.e., corneal neovascularization).
  • the terms “treat,” “treating,” and “treatment” refer to preventing the growth of recurrent lesions or reducing the recurrence rate of such lesions; slowing, delaying, or preventing the spread of lesions from the conjunctiva into the corneal region; reducing or alleviating one or more symptoms associated with pterygium, such as a burning sensation or gritty feeling in the eye; regression of lesion from the corneal region; and/or reducing, slowing the progression of, or alleviating secondary conditions associated with pterygium, such as hyperemia.
  • an ophthalmic formulation can be administered by any method known to those skilled in the art in view of the present disclosure, such as by topical administration, subconjunctival injection, or ophthalmic delivery by a device such as contact lens.
  • the ophthalmic formulation is topically administered, e.g., by eye drops or by swabbing, insertion of a contact lens loaded with the drug, or an erodible or non-erodible insert placed in the cul-de-sac of the eye.
  • a liquid nanosuspension can be administered as eye drops.
  • Nanoparticles in the form of eye drops can quickly access and associate with the cornea and conjunctiva, and those nanoparticles residing on the cornea and conjunctiva can contribute to drug levels predominantly in the ocular tissues of the anterior segment of the eye.
  • An ophthalmic formulation can be administered to any part of the eye, and is preferably administered to the surface of the eye for the treatment of an ocular surface disease.
  • Parameters such as the dosage amount, frequency of administration, and duration of administration of an ophthalmic formulation to a subject according to an embodiment of the invention are not limited in any particular way.
  • the optimum values of such parameters can depend on a variety of factors, such as the subject to be treated, the particular ocular surface disease to be treated, the severity of the disease, etc., and one of ordinary skill in the art will be able to determine the optimum values for such parameters in order to achieve the desired therapeutic or clinical outcome.
  • an ophthalmic formulation can be administered once per day, or more than once per day, such as twice, three times, four times, etc.
  • An exemplary and non-limiting dosing regimen comprises administering an ophthalmic formulation as eye drops three times per day for a duration of one to two weeks.
  • the invention also relates to a method of preparing an ophthalmic formulation, including a method of preparing any of the ophthalmic formulations described herein.
  • a method of preparing an ophthalmic formulation comprises optionally forming nanoparticles or microparticles of a tyrosine kinase inhibitor selected from the group consisting of Axitinib, Nintedanib, Sorafenib, Pazopanib, prodrugs thereof, and
  • the nanoparticles or microparticles can be formed in the presence of surfactant.
  • surfactants described herein can be used including, but not limited to, Tween 80, Tween 20, poloxamer 1 88, poloxamer 407, or tyloxapol, and preferably tyloxapol.
  • Any of the methods described herein can be used to form the nanoparticles or microparticles.
  • milling is used, such as a ball-milling process.
  • Embodiment 1 is an ophthalmic formulation comprising a therapeutically effective amount of Nintedanib, a prodrug thereof, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.
  • Embodiment 2 is the ophthalmic formulation of embodiment 1 , wherein the at least one pharmaceutically acceptable excipient is selected from the group consisting of surfactants, preservatives, viscosity regulators, pH-adjusting agents, stabilizers, and osmo-regulators.
  • the at least one pharmaceutically acceptable excipient is selected from the group consisting of surfactants, preservatives, viscosity regulators, pH-adjusting agents, stabilizers, and osmo-regulators.
  • Embodiment 3 is the ophthalmic formulation of embodiment 2, wherein the surfactant is selected from the group consisting of Tween 80, Tween 20, Poloxamer 188, poloxamer 407 and Tyloxapol.
  • Embodiment 4 is the ophthalmic formulation of embodiment 3, wherein the surfactant is Tyloxapol.
  • Embodiment 5 is the ophthalmic formulation of embodiment 2, wherein the viscosity regulator is selected from the group consisting of HPMC, Sodium
  • Carboxymethylcellulose Carbomer, Polycarbophil, PEG and HA or its salts and derivatives.
  • Embodiment 6 is the ophthalmic formulation according to any one of embodiments
  • the ophthalmic formulation comprises micronized particles or nanonized particles of Nintedanib, the prodrug thereof, or the pharmaceutically acceptable salt thereof.
  • Embodiment 7 is the ophthalmic formulation according to any one of embodiments 1 to 6, wherein the formulation is a liquid suspension, preferably a nanosuspension, for topical ocular administration.
  • Embodiment 8 is the ophthalmic formulation according to any one of embodiments 1 to 7, wherein a concentration of Nintedanib, the prodrug thereof, or pharmaceutically acceptable salt thereof is 0.01 % to 10% vv/v.
  • Embodiment 9 is an ophthalmic formulation comprising a therapeutically effective amount of micronized or nanonized particles comprising a tyrosine kinase inhibitor selected from the group consisting of Axitinib, Nintedanib, Sorafenib, Pazopanib, a prodrug thereof, and a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.
  • a tyrosine kinase inhibitor selected from the group consisting of Axitinib, Nintedanib, Sorafenib, Pazopanib, a prodrug thereof, and a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.
  • Embodiment 10 is the ophthalmic formulation of embodiment 9, wherein a
  • concentration of the tyrosine kinase inhibitor is 0.01 % to 10% w/v.
  • Embodiment 1 1 is the ophthalmic formulation according to embodiment 9 or embodiment 10, wherein the formulation is a liquid suspension, preferably a nanosuspension, for topical ocular administration.
  • Embodiment 12 is a method of treating an ocular surface disease in a subject in need thereof, the method comprising administering to an eye of the subject the ophthalmic formulation according to any one of embodiments 1 to 1 1.
  • Embodiment 13 is the method of embodiment 12, wherein the ocular surface disease is selected from the group consisting of angiogenesis in the front of the eye; corneal angiogenesis following keratitis, corneal transplantation, or keratoplasty; conjunctival degeneration (pinguecula) with slow proliferation; conjunctival papilloma; corneal angiogenesis due to hypoxia; hyperemia; hyperemia associated with pterygium; hyperthyroidism-induced eye congestion; dry eyes
  • NVG neovascular glaucoma
  • ocular cancer pterygium conjunctivae
  • recurrent pterygium pterygium
  • Embodiment 14 is the method of embodiment 1 3, wherein the ocular surface disease is hyperemia associated with pterygium, pterygium conjunctivae, or recurrent pterygium.
  • Embodiment 1 5 is a method of preparing the ophthalmic formulation of any one of embodiments 1 to 1 1 , comprising optionally forming microparticles or nanoparticles comprising a tyrosine kinase inhibitor selected from the group consisting of Axitinib, Nintedanib, Sorafenib, Pazopanib, a prodrug thereof, and a pharmaceutically acceptable salt thereof, and m ixing the tyrosine kinase inhibitor or the nanoparticles or microparticles thereof with at least one pharmaceutical ly acceptable excipient.
  • a tyrosine kinase inhibitor selected from the group consisting of Axitinib, Nintedanib, Sorafenib, Pazopanib, a prodrug thereof, and a pharmaceutically acceptable salt thereof
  • Embodiment 16 is the method of embodiment 15, wherein the m icroparticles or nanoparticles are formed by a milling process.
  • Embodiment 17 is the method of embodiment 15 or embodiment 16, wherein the m icroparticles or nanoparticles are formed in the presence of tyloxapol.
  • Embodiment 1 8 is the ophthalmic formulation of any one of embodiments 9 to 1 1 , wherein the nanoparticles have a D90 particle size of less than 1 ⁇ .
  • Embodiment 19 is use of the ophthalm ic form ulation of any one of embodiments 1 to
  • Embodiment 20 is the ophthalmic formulation of any one of embodiments 1 to 1 1 for use in treating an ocular surface disease.
  • Embodiment 21 is N intedanib, a prodrug thereof, or a pharmaceutically acceptable salt thereof for use in treating an ocular surface disease.
  • Embodiment 22 is use of Nintedanib, prodrug thereof, or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating an ocular surface disease.
  • Embodiment 23 is an ophthalmic formulation comprising:
  • the formulation is a liquid suspension for topical administration.
  • Embodiment 24 is the ophthalmic formulation of embodiment 23 having a D
  • Embodiment 25 is the ophthalmic formulation of embodiment 23 or embodiment 24 having a D 5 o particle size in a range of about 0.4- 1 .5 ⁇ .
  • Embodiment 26 is the ophthalmic formulation of any one of embodiments 23 to 25 having a D90 particle size in a range of about 0.5-3.0 ⁇ .
  • Embodiment 27 is a method of treating an ocular surface disease in a subject in need thereof, the method comprising administering to an eye of the subject the ophthalmic formulation according to any one of embodiments 23 to 26.
  • Embodiment 28 is the method of embodiment 27, wherein the ocular surface disease is selected from the group consisting of angiogenesis in the front of the eye; corneal angiogenesis following keratitis, corneal transplantation, or keratoplasty; conjunctival degeneration (pinguecula) with slow proliferation; conjunctival papilloma; corneal angiogenesis due to hypoxia; hyperemia; hyperemia associated with pterygium; hyperthyroidism-induced eye congestion; dry eyes
  • NVG neovascular glaucoma
  • ocular cancer pterygium conjunctivae
  • recurrent pterygium pterygium
  • Embodiment 29 is the method of embodiment 28, wherein the ocular surface disease is hyperemia associated with pterygium, pterygium conjunctivae, recurrent pterygium, or corneal angiogenesis.
  • Example 1 Preparation of Ophthalmic Suspension Containing Nintedanib Ethanesulfonate
  • HPMC stock and buffer preparation were prepared as follows.
  • HPMC solution was quantitatively transferred to a 200 mL volumetric flask and purified water was added to near final volume;
  • Steps (3)-(5) were repeated as needed, until Nintedanib Ethanesulfonate was uniformly dispersed/suspended and no visible aggregate remained (estimated total mixing and sonication time was about 1 .25 hours);
  • Diluent Preparation Water and methanol were mixed in a 1 : 1 ratio by volume to prepare the diluent. For the preparation of 1 L of diluent, 500 mL water was mixed with 500 mL of methanol.
  • Vehicle Preparation Vehicle (0.5 g) was diluted in 25 mL diluent and mixed well.
  • Nintedanib Ethanesulfonate Standard Preparation Nintedanib Ethanesulfonate (50.33 mg) was weighed into a 50 mL volumetric flask, diluent was added (40 mL), and the mixture was sonicated to dissolve. The mixture was diluted with diluent to obtain a standard stock solution of 1 .0066 mg/mL of Nintedanib Ethanesulfonate. The standard stock solution was further diluted with diluent and mixed well to obtain a standard preparation of 0.0604 mg/mL of Nintedanib Ethanesulfonate.
  • Ethanesulfonate suspension showed good suspension uniformity at all time points and for all locations in the vial, with an overall % relative standard deviation (% RSD) of the nine samples tested of less than 2%.
  • a 1 % (w/w) Axitinib ophthalmic formulation was prepared as a liquid suspension.
  • the components of the Axitinib liquid suspension are the same as shown in Table 1 , except the suspension contained 1 % Axitinib rather than 0.3% Nintedanib Ethanesulfonate.
  • the vehicle was also prepared as described above in Example 1.
  • Axitinib ophthalmic suspension was prepared according to the following procedure: ( 1 ) Axitinib ( 150.24 mg) and vehicle ( 14.8225 g) were weighed into a 20 mL scintillation vial, a stir bar was added, and the vial was securely capped;
  • the suspension uniformity for 1 % Axitinib was determined using a high performance liquid chromatography (HPLC) method in accordance with the following setup and preparations.
  • Diluent Preparation For the preparation of 1 L of diluent, 650 mL of 0.1 % H3PO4 (-85%) was mixed with 350 mL of water.
  • Vehicle Preparation Vehicle (0.5 g, prepared as described in Example 1 ) was diluted in 25 mL of diluent and mixed well.
  • Standard Preparation of Axitinib Axitinib (51 .1 2 mg) was mixed with di luent (40 mL) and sonicated to dissolve. The m ixture was further diluted with diluent to obtain a standard preparation having a final concentration of 0.2045 mg/mL of Axitinib.
  • Sample Preparation The 1 % Axitinib suspension preparation (0.5 g) was weighed out, mixed with diluent (20 mL), and sonicated to dissolve. The m ixture was further diluted with diluent and mixed well to obtain sample preparations having a final concentration of about 0.2 mg/mL of Axitinib.
  • the results of the particle size distribution analysis testing show that the average particle diameter of the 1 % Axitinib suspension prepared as described above is in the micrometer range.
  • the ophthalmic suspension has a Di o particle size of about 1 .6 ⁇ , a D 5 o of about 4.0 ⁇ and a D% of about 8.0 ⁇ .
  • the ophthalmic suspension containing Sorafenib Tosylate was prepared in the same manner as the Nintedanib Ethanesulfonate microsuspension and Axitinib microsuspension as described in Examples 1 and 2, respectively. All groups were dosed three times daily (TID) on Day 1 , 2, 3, and once on Day 4. A calibrated positive displacement pipette was used to administer a dose volume of 35 ⁇ /eye onto the globe of each eye.
  • Draize scoring was 0 for all observations during the course of the study, which was in agreement with the daily observations. None of the formulations tested resulted in any extended ocular irritation.
  • rabbits were euthanized via barbiturate overdose prior to both eyes being harvested and dissected for collection of aqueous humor, conjunctiva, and cornea. Following collection, tissues were weighed and snap-frozen on dry ice, and placed in a freezer at -80°C until processed for analysis. Concentrations of
  • Table 6 Mean concentrations of Nintedanib Ethanesulfonate, Sorafenib Tosylate, and Axitinib measured in the conjunctiva, cornea, and aqueous humor.
  • Example 4 Topical Efficacy of an Ophthalmic Suspension in an Animal Model of Cornea Suture-Induced Neovascularization
  • the aim of this study is to determine whether topical administration (eye drops) of ophthalmic suspensions of the invention result in decreased neovascularization in a rabbit model of cornea suture-induced neovascularization (Campos-Mollo et al., "New Corneal
  • Neovascularization Model in Rabbits for Angiogenesis Researc 'Op thcdmic Res. (2010) 45, 135- 141 ).
  • the procedure was conducted under a dissecting or surgical microscope.
  • the cornea of the right eye was exposed using an eyelid speculum.
  • the central corneal area was appropriately marked as considered necessary by the surgeon.
  • one 9.0 silk suture was placed intrastromally, approximately 1 mm from the limbus with 2 stromal incursions.
  • the outer point of suture placement was chosen near the limbus ( 1 -2 mm), and the inner suture point was chosen near the corneal center, equidistant from the limbus, to obtain standardized angiogenic responses.
  • the left eye remained untreated.
  • Dose formulations were administered by subconjunctival injection to the sutured right eye of each animal of the Avastin control group (5 mg) on Days 1 and 7, at a dose volume of 200 ⁇ iL/dose immediately post suture placement. Dose formulations were given three times daily (TID) for the group administered with suspension vehicle, 0.3% Axitinib, 0.3% Nintedanib
  • Ethanesulfonate, or 0.3% Sorafenib Tosylate for a duration of 14 days.
  • Dose formulations were administered 6 hours apart ⁇ 30 minutes by topical ocular instillation (onto the superior corneal surface) to the right eye using a calibrated positive displacement micropipette, to ensure contact with the conjunctiva.
  • the dosing volume was one 35 ⁇ _. drop per dose. After the dose was administered, the upper and lower eyelids were gently held together to prevent the loss of material and to distribute the dose across the eye.
  • Ocular imaging and neovascularization assessments were performed once pre- treatment, and also once on Days 7 and 14.
  • a pre-anesthetic cocktail of Ketamine ( 1 5 mg/kg) and Dexmedetomidine (0.25 mg/kg) was administered subcutaneously, and the animals were maintained with isoflurane/oxygen mix prior to and during the procedure.
  • Still images of the cornea were taken from both eyes (from the center of each eye, nasally and temporally). Images were evaluated qualitatively and quantitatively to assess the degree of corneal neovascularization (CNV), and to determine the area affected by CNV.
  • CNV corneal neovascularization
  • the length of the vessel incursion was measured from the limbus to the distal end of the encroaching CNV using a digital micrometer (in millimeters) for each selected image.
  • CNV was noted on Days 7 and 14 in the right eyes of animals given the suspension vehicle averaging I to 2.7 mm in length and affecting up to 50% of the corneal circumference, with slight to moderate branching of the vessels (see Figures 1 A and I B). In contrast, minimal to no CNV was noted in some animals given 5 mg Avastin/eye (see Figures 2A and 2B). Notably, animals treated with Avastin were observed to have minimal CNV on Day 14 (-0.5 to 1.1 mm), encompassing between 20 to 30% of the corneal circumference ( Figure 2B). [0176] On Day 7, CNV was not observed in animals given Axitinib or Nintedanib
  • Ethanesulfonate (see Figure 3A and Figure 4A).
  • vessels were approximately 0.5 mm in length, which covered approximate 20% of the corneal circumference and had very slight to moderate vessel branching.
  • the group treated with Nintedanib Ethanesulfonate was considered comparable to one given Avastin at Day 7.
  • the vessels were characterized as sparse and no branching was observed in the group administered with Nintedanib Ethanesulfonate ( Figure 4B).
  • the group given Nintedanib Ethanesulfonate was considered slightly more efficacious compared to the one given Avastin when comparing vessel length, surface area and vessel branching.
  • Ethanesulfonate was more efficacious, or at least comparable to Avastin in preventing or slowing CNV progression.
  • nanosuspensions were monitored at varying storage conditions, including different storage times and storage temperatures.
  • the nanosuspensions were tested after 20 days and 30 days after storage at room temperature, 40°C, or 60°C. Some impurities were detected in all samples tested, after storage for 20 days and 30 days at room temperature, 40 ° C and 60 ° C similar to the initial test value.
  • formulation 4 containing Tyloxapol in particular showed little or no increase in the particle size after storage for 20 days and 30 days at all temperatures tested.
  • nanosuspensions was measured after storage for 7 days, 14 days, and 28 days at 4°C, room temperature, 40°C, and 60°C. As shown in Table 1 1 below, little to no increase in the particle size was found in nanosuspensions containing HPMC (Formulation 1 ).
  • Aqueous solubility of Nintedanib varies with the pH value of the formulation, which can lead to subsequent changes in particle size. Therefore, the particle size stability of nanosuspensions with varying pH values was evaluated. The pH of the formulation was adjusted to the indicated value prior to measuring the particle size of the initial suspension. The results for formulations with pH values of 5.8, 6.5, 7.0, and 7.4 are reported in Table 12.
  • nintedanib nanosuspensions containing various surfactants or at different pH as l isted in Table 13 below were allowed to sit for 1 hour, followed by shaking 10 times by hand (amplitude; 10 cm), After shaking, samples were taken from top, midd le, and bottom parts of the nanosuspensions and analyzed for Nintedanib content.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dispersion Chemistry (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Ophthalmic formulations containing tyrosine kinase inhibitors, such as Nintedanib, Axitinib, Sorafenib, and Pazopanib are described. The ophthalmic formulations can contain microparticles or nanoparticles of the tyrosine kinase inhibitor. Also described are methods of using the ophthalmic formulations for treating ocular surface diseases, such pterygium, including recurrent pterygium, and hyperemia associated with pterygium.

Description

TITLE OF THE INVENTION
[0001 J Ophthalmic Formulations of Tyrosine Kinase Inhibitors, Methods of Use Thereof and Preparation Methods Thereof
CROSS REFERENCE TO RELATED APPLICATION
[0002] This application is entitled to priority pursuant to 35 U.S.C. § 1 19(e) to U.S.
Provisional Application No. 62/ 1 83, 180, filed June 22, 201 5, and the disclosure of which is incorporated by reference herein in its entirety.
FIELD OF THE INVENTION
[0003] The invention relates to ophthalmic formulations comprising tyrosine kinase inhibitors, such as Nintedanib, Axitinib, and Sorafenib, and the use of such ophthalmic
formulations for the treatment of ocular surface diseases.
BACKGROUND OF THE INVENTION
[0004] Ophthalmic medication is usually applied to the eye to treat the outside of the eye, as well as to provide intraocular treatment through the cornea. Typically, most ocular diseases are treated by topical drug application in the form of solutions, suspensions, and gels. A topical drug delivery system for ophthalmic uses should possess certain desirable properties, such as good corneal and conjunctival penetration of the active drug, prolonged pre-corneal residence time, easy instillation, non-irritating, and comfortable to minimize lachrymation and reflex blinking. It should also have appropriate rheological properties.
[0005] However, conventional dosage forms for ophthalmic applications suffer from the problems of poor ocular bioavailability due to various anatomical and pathophysiological barriers in the eye. Also, many compounds considered potentially useful in treating ocular
neovascularization and disorders related to vascular permeability are often poorly soluble in water. Conventional approaches often attempt to solubilize insoluble drugs with the use of high concentrations of co-solvents, but this poses problems of toxicity and ocular tolerability.
[0006[ Moreover, for certain ophthalmological conditions, an effective topical therapeutic has yet to be developed. For example, the only currently approved method to treat pterygium is surgery. Pterygium is a fleshy lesion or growth originating from the conjunctiva of the eye.
Because surgery is invasive to the patient and patients are typically asymptomatic until the lesion encroaches into the cornea and blurs vision, patients are often required to live with the lesion on their eye until vision is impaired and surgery becomes necessary. Additionally, there is a high chance of recurrence of the lesion following surgery, which requires additional surgeries to remove the recurrent lesions. [0007] Recently, tyrosine kinase inh ibitors, such as Axitinib, Pazopanib, and Sorafenib have been used for ophthalmological applications. Compositions suitable for topical application to the eye containing such compounds as a therapeutically active ingredient are disclosed in U.S. Patent Appl ication Publication No. 20 1 5/0 1 64790; U.S. Patent Appl ication Publication No.
2014/0235678; U.S. Patent Application Publication No. 201 1 /0 142923 ; and U.S. Patent
Application Publication No. 2015/0141448. See also PCT Patent Application Publication WO 2014/074823, which discloses injectable compositions for administration to the suprachoroidal space (SCS) of the eye for treating posterior ocular disorders and choroidal maladies; and Seo et al. "Inhibition of Corneal Neovascularization in Rats by Systemic Adm inistration of Sorafenib" Cornea (2012) 3 1 (8), 907, which evaluates the effects of orally administered sorafenib on corneal neovascularization in rat models.
[0008] Despite the progress described in the art of ophthalmological formulations, there is a need in the art for improved formulations and treatment methods of ophthalmic disorders, and particularly for those disorders for which there is no non-invasive conventional alternative, such as pterygium. The formulation for ophthalmological applications should be capable of being easily administered without causing eye irritation, thus increasing patient compliance. The formulation should also deliver an active agent to the eye at a concentration which is sufficient for effective therapy.
BRIEF SUMMARY OF THE INVENTION
[0009] The invention satisfies this need by providing novel ophthalm ic formulations that are efficacious in treating ocular diseases, particularly ocular surface diseases, such as pterygium. The ophthalmic formulations of the invention can be administered topically, are well tolerated, and have little to no toxicity.
[0010] In one general aspect, the invention relates to an ophthalmic formulation comprising a therapeutically effective amount of Nintedanib, a prodrug thereof, or a
pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.
[0011 ] In an embodiment of the invention, the ophthalmic formulation comprises
Nintedanib.
[0012] In an embodiment of the invention, the ophthalmic formulation comprises Nintedanib Ethanesulfonate.
[0013] In an embodiment of the invention, the ophthalmic formulation further comprises tyloxapol as a surfactant.
[0014] In an embodiment of the invention, the ophthalmic formulation is a liquid suspension. [0015] In an embodiment of the invention, the ophthalmic formulation is a topical ocular composition.
[0016] In particular embodiments of the invention, the ophthalmic formulation comprises a therapeutically effective amount of micronized or nanonized particles of a tyrosine kinase inhibitor selected from the group consisting of Axitinib, Nintedanib, Sorafenib, Pazopanib, a pharmaceutical ly acceptable prodrug thereof, and a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.
[0017] In a preferred embodiment of the invention, the ophthalm ic formulation comprises nanonized particles of Nintedanib or a pharmaceutically acceptable salt thereof.
[0018] In another general aspect, the invention relates to a method of treating an ocular surface disease in a subject in need thereof, the method comprising administering to an eye of the subject an ophthalmic formulation of the invention.
[0019] In an embodiment of the invention, the ocular surface disease is hyperemia associated with pterygium, pterygium conj unctivae, or recurrent pterygium.
[0020] In a preferred embodiment of the invention, adminstration of the ophthalmic formulation is topical ocular administration.
[0021 ] And in yet another general aspect, the invention relates to a method of preparing an ophthalmic formulation of the invention, comprising combining a tyrosine kinase inhibitor selected from the group consisting of Axitinib, Nintedanib, Sorafenib, Pazopanib, a
pharmaceutical ly acceptable prodrug thereof, and pharmaceutically acceptable salt thereof with at least one pharmaceutically acceptable excipient, and preferably the method further comprises form ing microparticles or nanoparticles of the tyrosine kinase inhibitor for inclusion in the ophthalmic formulation of the invention.
[0022] The invention also relates to use of an ophthalmic formulation of the invention in the preparation of a medicament for treating an ocular surface disease.
BRIEF DESCRIPTION OF THE DRAWINGS
[0023] The foregoing summary, as well as the fol lowing detailed description of the invention, wil l be better understood when read in conj unction with the appended drawings. It should be understood that the invention is not limited to the precise embodiments shown in the drawings.
[0024] In the drawings:
[0025] Figures 1 A and I B show representative photographic images of corneal neovascularization in a New Zealand white rabbit model of cornea suture-induced
neovascularization upon treatment with suspension vehicle administered three times daily (TID) for a duration of 14 days; Figure 1 A shows m inimal neovascularization on day 7; Figure I B shows neovascularization of the cornea on day 14 with the arrow pointing to the area of neovascularization;
[0026] Figures 2A and 2B show representative photographic images of corneal
neovascularization in a New Zealand white rabbit model of cornea suture-induced
neovascularization upon treatment with Avastin; Avastin was administered by subconjunctival injection to the sutured eye on day 1 and day 7 post-suture placement; Figure 2A and 2B show little to no neovascularization of the cornea on clay 7 and 14, respectively; the arrow in Figure 2B points to the area of the eye in which any neovascularization would be expected to be observed;
[0027] Figures 3A and 3B show representative photographic images of corneal
neovascularization in a New Zealand white rabbit model of cornea suture-induced
neovascularization upon treatment with 0.3% Axitinib administered three times daily for a duration of 14 days; Figure 3 A and 3B show no neovascularization of the cornea on day 7 and 14, respectively;
[0028] Figures 4A and 4B show representative photographic images of corneal
neovascularization in a New Zealand white rabbit model of cornea suture-induced
neovascularization upon treatment with 0.3% Nintedanib Ethanesulfonate administered three times daily for a duration of 14 days; Figure 4A and 4B show no neovascularization of the cornea on day 7 and 14, respectively;
[0029] Figures 5A and 5B show representative photographic images of corneal
neovascularization in a New Zealand white rabbit model of cornea suture-induced
neovascularization upon treatment with 0.3% Sorafenib administered three times daily for a duration of 14 days; Figure 5A and 5B show little neovascularization of the cornea on day 7 and 14, respectively, with the arrow pointing to the area of neovascularization; and
[0030] Figure 6 is a distribution diagram that shows the effect of different surfactants on the size distribution of Nintedanib particle.
DETAILED DESCRIPTION OF THE INVENTION
[0031 ] Various publications, articles and patents are cited or described in the background and throughout the specification; each of these references is herein incorporated by reference in its entirety. Discussion of documents, acts, materials, devices, articles or the like which has been included in the present specification is for the purpose of providing context for the invention.
Such discussion is not an admission that any or all of these matters form part of the prior art with respect to any inventions disclosed or claimed.
[0032] Unless defined otherwise, all technical and scientific terms used herein have the same meaning commonly understood to one of ordinary skill in the art to which this invention pertains. Otherwise, certain terms used herein have the meanings as set in the specification. All patents, published patent applications and publications cited herein are incorporated by reference as if set forth fully herein. It must be noted that as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural reference unless the context clearly dictates otherwise.
[0033] The phrase "pharmaceutically acceptable salt" as used herein means those salts of a compound of interest that are safe and effective for administration to a mammal and that possess the desired biological activity. Pharmaceutically acceptable acid salts include, but are not limited to hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, carbonate, bicarbonate, acetate, lactate, salicylate, citrate, tartrate, propionate, butyrate, pyruvate, oxalate, malonate, pantothenate, bitartarte, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, /?-toIuenesulfonate and pamoate (i.e., 1 , 1 '- methylene-bis-(2-hydroxy-3-naphthoate)) salts. Suitable base salts include, but are not limited to, aluminum, calcium, lithium, magnesium, potassium, sodium, zinc, bismuth, and diethanolamine salts. For a review of pharmaceutically acceptable salts see Berge et al. , J. Pharm. Sci. ( 1977) 66, 1 - 1 9, incorporated herein by reference.
[0034] The invention relates to ophthalmic formulations and methods of using the ophthalmic formulations to treat ocular surface disorders. An "ophthalmic formulation" as used herein refers to any pharmaceutical composition suitable for ocular administration, i.e., administration to the eye. Preferably, the ophthalmic formulation is suitable for topical administration to the eye, although the ophthalmic formulation can be formulated as a
composition for other routes of administration such as intravitreous injection or subconjunctival injection. As illustrative and non-limiting examples, ophthalmic formulations suitable for topical administration can be in the form of a liquid, such as a suspension or a solution; cream; ointment; gel; gel-forming liquid; suspension containing liposomes or micelles; spray formulation; emulsion; erodible or non-erodible carriers that can be inserted into the cul-de-sac of the eye. In a preferred embodiment of the invention, the ophthalmic formulation is a liquid suspension.
[0035] According to embodiments of the invention, an ophthalmic formulation comprises a therapeutically effective amount of a tyrosine kinase inhibitor. The term "therapeutically e ffective amount" means an amount of a therapeutically active compound needed to elicit the desired biological or clinical effect. According to embodiments of the invention, "a
therapeutically effective amount" is the amount of a tyrosine kinase inhibitor needed to treat an ophthalmic disorder or condition, such as an ocular surface disease. [0036] The term "tyrosine kinase inhibitor (TKi)" as used herein refers to a therapeutically active compound that is capable of inhibiting the activity of one or more tyrosine kinases, such as, for example, platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptor (FGFR), vascular endothelial growth factor receptor (VEGFR), and Fms-like tyrosine kinase-3 (FLT3). Examples of tyrosine kinase inhibitors suitable for use with the invention include, but are not limited to, Nintedanib, Sorafenib, Axitinib, Pazopanib, pharmaceutically acceptable prodrugs thereof, and pharmaceutically acceptable salts thereof. Preferably, the tyrosine kinase inhibitor is Nintedanib or Axitinib, and more preferably is Nintedanib. Preferred pharmaceutically acceptable salts of Nintedanib include Nintedanib ethanesulfonate. Nintedanib, Sorafenib, Axitinib, and Pazopanib have the following formula (I) (II), (III), and (IV) respectively:
Figure imgf000007_0001
[0037] Prodrugs of the above mentioned tyrosine kinase inhibitors are also contemplated herein. The term "prodrug" as used herein means a compound that is converted in vivo to yield a compound of Formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof. A prodrug is typically a drug precursor that is converted in vivo to a biologically active compound or drug. The in vivo conversion can occur by various mechanisms, including metabolic and/or chemical processes, such as, for example, through hydrolysis in the blood or target tissue, such as the eyes (see, e.g., Rautio et al., Nature Reviews 7, 255-270 (2008)). A discussion of the use of prodrugs is also provided by T. Higuchi and W. Stella, "Pro-drugs as Novel Delivery Systems," Vol. 41 of the A.C.S. Symposium Series; Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987; and M Barot et al., "ProDrug Strategies in Ocular Drug Delivery" Med Chem, 8(4): 753-768, 2012. [0038] As illustrative examples of prodrugs in accordance with embodiments of the invention, if a compound of Formula (1), (II), (III), or (IV) incorporates an amine functional group, a prodrug can be formed by replacing a hydrogen atom of the amine, urea or amide group with a functional group such as, for example, -C(0)R or -C(0)OR; or a prodrug can be formed by replacing one or two hydrogen atom(s) of a sulfonamide group with one to two functional group(s), such as -C(0)R or-RR', wherein R and R' are each independently (Ci -Cio)alkyl, (C3- C7)cycIoalkyI, or benzyl. Alternatively, -C(0)R can be a natural a-aminoacyl or - C(OH)C(0)OY' , wherein Y1 is H, (C C6)alkyl, benzyl, or -C(OY2)Y3; Y2 is (C, -C4)alkyl; Y3 is (C, -C6)alkyl, carboxy(Ci-C6)alkyl, amino(Ci-C4)alkyl, mono-N- or di-N, N-(C r
C6)aikylaminoalkyl, or -C(Y4)Y5; Y4 is H or methyl; and Y5 is mono-N- or di-N, N-(C
C6)alkylamino morpholino, piperidin- 1 -yl, or pyrrolidin- l -yl, and the like.
[0039] The tyrosine kinases FGFR, PDGFR, and VEGFR have been implicated in idiopathothic pulmonary fibrosis. Nintedanib Ethanesulfonate was previously approved for the treatment of idiopathic pulmonary fibrosis, as well as for treating locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) in combination with docetaxel. Nintedanib has thus previously been used for oncology treatment, and to the best of the knowledge of the inventors, there is no ophthalmic drug containing Nintedanib on the market or in clinical trials.
[0040] In one embodiment of the invention, the tyrosine kinase inhibitor is Nintedanib, a prodrug thereof, or a pharmaceutically acceptable salt thereof, such as Nintedanib Ethanesulfonate.
[0041] In another embodiment of the invention, the tyrosine kinase inhibitor is Axitinib, a prodrug thereof, or a pharmaceutically acceptable salt thereof.
[0042] In another embodiment of the invention, the tyrosine kinase inhibitor is Sorafenib, a prodrug thereof, or a pharmaceutically acceptable salt thereof.
[0043] In another embodiment of the invention, the tyrosine kinase inhibitor is Pazopanib, a pharmaceutically acceptable salt thereof, or a prodrug thereof.
[0044] According to embodiments of the invention, an ophthalmic formulation comprises at least one pharmaceutically acceptable excipient. Examples of pharmaceutically acceptable excipients that can be used include, but are not limited to, surfactants, preservatives, viscosity regulators, pH-active components (e.g., pH-adjusting agents, buffering agents etc.), stabilizers, and osmo-regulators (tonicity adjusters).
[0045] Suitable surfactants that can be used in an ophthalmic formulation according to the invention include, but are not limited to, non-ionic surfactants such as poloxamers,
polyoxyethylene fatty acid glycerides and oils, polyoxyethylene alkyl ethers, polyoxyethylene fatty acid esters, sorbitan esters, polyoxyethylene sorbitan esters, propylene glycol fatty acid esters, fatty acids, glyceryl fatty acid esters, a-tocopheryl polyethylene glycol succinate (TPGS), polyethoxy alkylaryl ether polymers, polymers of alkyl aryl polyether alcohol and the like..
Preferably, the surfactant is Tween 80, Tween 20, poloxamer 1 88, poloxamer 407 or tyloxapol.
[0046| In a preferred embodiment of the invention, an ophthalmic formulation further comprises tyloxapol as a surfactant.
[0047] Suitable viscosity regulators that can be used in an ophthalmic formulation according to the invention include, but are not limited to, hydroxypropyl methylcellulose (HPMC), hydroxypropylcellulose (HPC), carboxymethylcellulose (CMC), methylcellulose (MC), hydroxyethylcellulose (HEC), cellulose and derivatives thereof, polycarbophil, polyoxyethylene glycol (PEG), hyaluronic acid (HA), amylase and derivatives thereof, amylopectins and derivatives thereof, dextran and derivatives thereof, polyvinylpyrrolidone (PVP), polyvinyl alcohol (PVA), and acrylic polymers such as derivatives of polyacrylic or polymethacrylic acid including hydroxylmethyl methacrylate (HEMA), carbomer or a mixture thereof.
[0048] In a preferred embodiment, the viscosity regulator is selected from the group consisting of HPMC, sodium carboxymethylcellulose, carbomer, polycarbophil, PEG, and HA.
[0049] In a more preferred embodiment, the viscosity regulator is HPMC.
[0050] Suitable pH active components, such as buffering agents or pH-adjusting agents, that can be used in an ophthalmic formulation according to the invention include, but are not limited to, acids, such as boric acid, citric acid, hydrochloric acid, and salts thereof; and alkali metal salts, such as disodium phosphate, monosodium phosphate, sodium borate, sodium citrate, sodium hydroxide, and potassium phosphates.
[0051] According to embodiments of the invention, the pH of an ophthalmic formulation can vary from about 5.0 to 8.0, such as 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, or 8.0. Preferably, the pH is between about 6.0 and 7.5. The pH can be adjusted to control the particle size distribution of the tyrosine kinase inhibitor in the ophthalmic formulation. The pH can also be adjusted to provide for optimal chemical stability of the active ingredient.
[0052] According to preferred embodiments of the invention, the tonicity of an ophthalmic formulation is isotonic, or slightly hypotonic as compared to tears, in order to combat any hypertonicity of tears caused by evaporation and/or disease. For example, the osmolality of an isotonic or slightly hypotonic ophthalmic formulation of the invention can be about 250-300 milliosmoles per kilogram (mOsm/kg). A tonicity adjustor can be used to bring the osmolality of the formulation to a level at or near 250-350 mOsm/kg. Suitable tonicity adjusters that can be used include, but are not limited to, ionic and nonionic osmotic adjusting agents such as sodium chloride, potassium chloride, dextran, cyclodextrins, mannitol, dextrose, glycerol, sorbitol, boric acid, borax and propylene glycol and combinations thereof. [0053] Preservatives that can be used in an ophthalmic formulation according to the invention include, but are not limited to, benzalkonium chloride, cetrimide, cetylpyridinium chloride, benzododecinium bromide, benzethonium chloride, thiomersal, chlorobutanol, benzyl alcohol, phenoxyethanol, phenylethyl alcohol, sorbic acid, methyl and propyl parabens, chlorhexidine digluconate, EDTA, polyquad, purite, perborate-based preservatives, other mercuric compounds, zinc polyol complexes, or mixtures thereof.
[0054] In a particular embodiment of the invention, benzalkonium chloride is included in the ophthalmic formulation as a preservative. The benzalkonium chloride is preferably present in an amount from about 0.001 to 0.02% w/v, such as 0.001 %, 0.005%, 0.01 %, or 0.02%, and most preferably about 0.005% w/v.
[0055] According to embodiments of the invention, a concentration of the tyrosine kinase inhibitor in an ophthalmic formu lation ranges from about 0.0 1 % to about 1 0% w/v, such as 0.01 %, 0.03%, 0.05%, 0.1 %, 0.3%, 0.5%, 1 %, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, or 10%.
[0056] As used herein, a "particle of a tyrosine kinase inhibitor" refers to a particle comprising the tyrosine kinase inhibitor. A "particle" as used herein can be a droplet, vesicle, a lipsome, a micelle, etc. According to embodiments of the invention, a particle of a tyrosine kinase inhibitor can optionally comprise other ingredients, such as phosphochol ine, fatty acid glycerides, PLGA and PLA.
[0057] In certain embodiments of the invention, an ophthalm ic formulation comprises "micronized," preferably "nanonized," particles that comprise a tyrosine kinase inhibitor, such as nanonized or micronized particles of Nintedanib, Sorafenib, Axitinib, or Pazopanib.
[0058] As used herein, the terms "nanonized particle," "nano-sized particle,"
"nanoparticle," and "sub-micron particle" all refer to a particle comprising a therapeutically active compound having an average particle diameter that is in the sub-micron range, and ranges from about 1 nanometer (nm) to less than about 1 000 nm, preferably 1 00 nm to 900 nm, and more preferably about 200 nm to about 800 nm. The term "nanonize" refers to a process of reducing the particle size, i.e., the average diameter of the particle, into the nanometer range.
[0059] As used herein, the terms "micronized particle," "micro-sized particle," and
"microparticle" all refer to a particle comprising a therapeutically active compound having an average particle diameter that ranges from about 0.5 μιη to about 1000 μιη, preferably about 0.5 μιη to about 1 00 μηι, and more preferably about 0.5 μιη to about 10 μιη. The term "micronize" refers to a process of reducing the particle size, i.e., the average diameter of the particle, down to a few microns, such as in the range of about 1 μιη to about 1 0 μιη. [0060] In one embodiment of the invention, an ophthalmic formulation is a liquid suspension. The liquid suspension is preferably suitable for topical administration. The liquid suspension can be a "nanosuspension" or a "microsuspension."
[0061] A "nanosuspension" as used herein refers to a suspension comprising particles of a tyrosine kinase inhibitor with at least a majority of the particles in the suspension as nanoparticles having an average particle diameter of less than about 1 μιη. A nanosuspension can also have a few particles in the suspension having an average particle diameter greater than about 1 μιη. For a nanosuspension for topical ocular use, the D90 particle size is about 1 μηι or less than 1 .5 μιτι, and the D50 particle size is less than Ι μηι. The D90 particle size of a liquid suspension is the diameter at which 90% by volume of the particles in the suspension are smaller in their longest dimension, as measured by any conventional particle size measuring technique known to those skilled in the art. The D5o particle size of a liquid suspension is the diameter at which 50% by volume of the particles in the suspension are smaller in their longest dimension, as measured by any
conventional particle size measuring technique known to those skilled in the art. The D50 particle size is therefore a measure of volume median particle size, but is sometimes referred to as
'"average" or "mean" particle size. Techniques for determining particle size include, but are not limited to, sedimentation field flow fractionation, photon correlation spectroscopy, laser light scattering, and disk centrifugation.
[0062] A "microsuspension" as used herein refers to a suspension comprising particles of a tyrosine kinase inhibitor with at least a majority of the particles in the suspension as
microparticles having an average particle diameter of about 1 μηι to 1000 μιη. A microsuspension can also have a few particles in the suspension having an average particle diameter less than about 1 μηι. For a microsuspension for topical ocular use, the D90 particle size is about less than 20 μιη, and the D50 particle size is about less than 10 μιη.
[0063] In one embodiment of the invention, an ophthalmic formulation comprises nanoparticles or microparticles comprising Nintedanib, or a prodrug thereof, or a
pharmaceutically acceptable salt thereof, such as Nintedanib ethanesulfonate.
[0064] In another embodiment of the invention, an ophthalmic formulation comprises nanoparticles or microparticles comprising Axitinib, or a prodrug thereof, or a pharmaceutically acceptable salt thereof.
[0065] In another embodiment of the invention, an ophthalmic formulation comprises nanoparticles or microparticles comprising Sorafenib, or a prodrug thereof, or a pharmaceuticall acceptable salt thereof. [0066] In another embodiment of the invention, an ophthalmic formulation comprises nanoparticles or microparticles comprising Pazopanib, or a prodrug thereof, or a pharmaceutically acceptable salt thereof.
[0067] In a preferred embodiment, an ophthalmic formulation comprises nanoparticles comprising a tyrosine kinase inhibitor having a D 0 particle size of less than 1 μηι.
[0068] Liquid medium can be used in preparing solutions, suspensions and emulsions as ophthalmic formulations of the invention. For example, the tyrosine kinase inhibitor or nanoparticles thereof described herein can be suspended in a pharmaceutically acceptable liquid medium such as water, an organic solvent, a mixture of water and one or more organic solvents, or pharmaceutically acceptable oils or fats. The liquid medium can contain other suitable pharmaceutical additives including, but not limited to, surfactants, preservatives, viscosity regulators, pH-adj listing agents, stabilizers, and osmo-regulators known to those skilled in the art in view of the present disclosure.
[0069] Micronized or nanonized particles comprising a tyrosine kinase inhibitor for use in the ophthalmic formulation of the invention can be made using any technique known to those skilled in the art in view of the present disclosure. Examples of techniques for producing m icronized or nanonized particles include, but are not limited to, milling, homogenization, precipitation, freezing, template emulsion techniques, liposome formation, emulsion,
m icroemulsion method, solvent extraction/evaporation methods, supercritical fluid technology, spray drying, ultrasonic technology, or any combination thereof. For example, homogenization and milling processes can be combined with a precipitation step in order to achieve smaller particles of narrower size distribution.
[0070] In one embodiment, microparticles or nanoparticles comprising a tyrosine kinase inhibitor are made by dry or wet milling. Examples of mills commonly used involve dry-type m ills, such as jet mil l, conventional and planetary bal l mill, vibrational rod m il l, and hammer and knife mill. These dry-type mills are used to grind a drug alone to afford particles of several microns in diameter. However, it is difficult to obtain finer particles, particularly submicron particles of less than 1 μιτι in diameter, using conventional dry m illing methods. It has been further noted that a wet milling may be useful to further reduce particle size (see, e.g., (Lachman et al., "The Theory and Practice of Industrial Pharmacy," Milling, 45 ( 1986)). For wet milling, media mills, such as planetary ball and bead mills which use balls or beads as the grinding media, respectively, and medialess m i lls, such as a high-pressure homogenizer, are commonly used. A typical wet milling process comprises dispersing a compound in a liquid dispersion medium in which the compound is poorly soluble, followed by applying mechanical means in the presence of grinding media to obtain a dispersion in which the particle size of the compound is reduced to the desired average particle diameter. The dispersion medium can be, for example, water, safflower oil, ethanol, t-butanol, glycerin, polyethylene glycol (PEG), hexane, or glycol. The particle size of the compound can also be reduced by milling in the presence of at least one surface stabilizer. Alternatively, the compound can be contacted with one or more surface stabil izers after attrition. Other components, such as a diluent, can be added to a composition containing the compound and surface stabilizer during the size reduction process. Dispersions can be manufactured continuously or in a batch mode.
[0071 ] The mechan ical means appl ied to reduce the particle size during the milling process can take the form of a dispersion mill. Suitable dispersion m ills include a ball mill, an attrition mill, a vibratory mill, and media mills such as a sand mill and a bead mill. Preferably, a media m i l l is used due to the relatively shorter m i lling time required to provide the desired reduction in particle size. For media milling, the apparent viscosity of a mixture prior to milling (e.g., mixture containing the active pharmaceutical ingredient and wetting agent dissolved in water) is preferably between 1 00 to about 1 000 centipoise. For ball m i lling, the apparent viscosity of a mixture prior to milling (e.g., mixture containing the active pharmaceutical ingredient and wetting agent dissolved in water) is preferably between 1 to about 1 00 centipoise. Such ranges tend to afford an optimal balance between efficient particle size reduction and media erosion, but are in no way l imiting. Any other mechanical means known to those skilled in the art in view of the present disclosure can be used to reduce the particle size.
[0072] Any material known to those skilled in the art in view of the present disclosure can be used as the grinding media for particle size reduction during m illing. For example, the grinding media is selected from rigid media, preferably spherical or particulate in form, and ranging in size from about 0.01 mm to 3 mm, and more preferably 0.01 mm to less than 1 mm. For fine grinding, the grinding media is preferably from 0.02 to 2 mm, and more preferably from 0.03 to 1 mm in size. Such grinding media can provide particles for use in the invention with shorter processing times and impart less wear to the mi lling equipment, which are desirable advantages. Non-limiting examples of grinding material include zirconium oxide, such as 95% ZrO stabilized with magnesium ; zirconium silicate; ceramic; stainless steel; titanium; aluminum; yttrium; and glass. The grinding media can contain particles that are preferably spherical in shape, e.g., beads, made of polymeric resin, glass, zirconium silicate, or other suitable material.
Alternatively, the grinding media can comprise a core having a coating of a polymeric resin adhered thereon.
[0073] After the particle reduction step by grinding during the milling process, the grinding media can be separated from milled nanoparticles using conventional separation techniques in a secondary process such as by simple filtration, sieving through a mesh filter or screen, and the like. Other separation techniques, such as centrifugation can also be employed. Alternatively, a screen can be utilized during the milling process to remove the grinding media following completion of particle size reduction.
[0074] According to embodiments of the invention, precipitation can be used to form nanoparticles of a tyrosine kinase inhibitor suitable for use in the ophthalmic formulations of the invention. Precipitation includes nanoprecipitation. In general, nanoprecipitation is the nucleation of small aggregates of macromolecules followed by aggregation of these nuclei. One nanoprecipitation process that can be used is nanomorph, which is a process by which molecules with low aqueous solubility are converted from a crystalline state into amorphous nanoparticles at the industrial scale by dissolving the tyrosine kinase inhibitor in a solvent, and feeding into a mixing chamber to rapidly mix with a non-solvent for the active pharmaceutical ingredient (API) (i.e., solvent in which the API is not very soluble, or does not dissolve well in). Another nanoprecipitation approach involves the use of the MicroJet Reactor technology, by which organic solutions of the tyrosine kinase inhibitor and one or more polymers, such as HPMC, sodium carboxymethylcellulose, carbomer, polycarbophil, PEG, and HA collide with a non-solvent for the API in the middle of a gas-filled chamber. The small diameter combined with a high velocity of the jets result in a very fast and intensive mixing and precipitation of insoluble reaction products. The influx of gas carries the dispersion out of the reaction chamber. Although particle size and size distribution depend on desolvation velocity and precipitation kinetics of polymer(s) and compound, small particles with narrow size distribution can be achieved by this method.
[0075] Another method of forming nanoparticles that can be used in accordance with the invention is template emulsion. Template emulsion creates nanostructured particles with controlled particle size distribution and rapid dissolution performance. Template emulsion involves preparing an oil-in-water emulsion, then swelling in a non-aqueous solution comprising the selected tyrosine kinase inhibitor and stabilizer. The solvent and water are then removed. The resulting particle size distribution of the tyrosine kinase inhibitor is usually based on the size of the emulsion droplets prior to loading with the tyrosine kinase inhibitor, and optimizing the size of the emulsion droplets can be used to control the particle size distribution of the tyrosine kinase inhibitor. Furthermore, through selected use of solvents and stabilizers, emulsion stability is achieved with no or suppressed Oswald ripening. By controlling the processing conditions, such as the size of emulsion droplets, solvents, and stabilizers, various particle morphologies can be achieved.
[0076] An exemplary homogenization method, i.e., forming a suspension comprising nanoparticles or microparticles, and more preferably a suspension comprising nanoparticles. comprises dispersing particles of a tyrosine kinase inhibitor, a prodrug thereof, or a pharmaceutically acceptable salt thereof, in a liquid dispersion medium, followed by
homogenization to reduce the particle size to the desired effective average particle size.
Specifically, in a high pressure homogenization process, a pre-suspension of the particles of tyrosine kinase inhibitor having a particle size in the micrometer range passes through a very small homogenizer gap. This creates cavitation forces of high turbulence and shear, combined with compression, acceleration, pressure drop, and impact, which are sufficiently high to disintegrate microparticles of the tyrosine kinase inhibitor to nanoparticles as the suspension leaves the gap and normal air pressure is reached again (Microfluidizef processor, Microfliiidics, USA). The homogenization pressure and number of homogenization cycles are important parameters in optimizing the process, and one of ordinary skill in the art would be able to determine the optimum values for such parameters in order to achieve the desired results.
[0077] In other embodiments of the invention, an ophthalmic formulation comprises particles of a tyrosine kinase inhibitor, or a prodrug thereof, or pharmaceutically acceptable salt thereof dispersed in a composition containing a bioadhesive material. A bioadhesive material can be a cationic bioadhesive or an anionic bioadhesive. Particles of the tyrosine kinase inhibitor, such as microparticles or nanoparticles, and preferably nanoparticles of the tyrosine kinase inhibitor, can be contacted with a solution comprising a bioadhesive that associates with and/or coats the particles. In some embodiments, particles having one or more coatings of the bioadhesive can be formed by layer-by-layer methods. In other embodiments, a hollow matrix can first be assembled from the bioadhesive in the solution before the tyrosine kinase inhibitor is encapsulated to form the particle. The bioadhesive coating can be further stabilized by the addition of an oppositely charged polymer, which forms a firm electrostatic complex with the bioadhesive coating. This results in the appearance of a very thin, but stable layer or shell around each nanoparticle. This shell can prevent particle agglomeration, and can be easily and reproducibly formed on the surface of the nanoparticle.
[0078] A particle coated with the bioadhesive as described herein can have any suitable shape and/or size. In some embodiments, a coated particle has a shape substantially similar to the shape of the core. According to embodiments of the invention, the coated particle described herein can be a nanoparticle or a microparticle.
[0079] In certain embodiments, the particles of the tyrosine kinase inhibitor described herein, such as nanoparticles or microparticles, can further comprise surface-altering moieties and/or agents that affect the zeta-potential of the particle. Examples of such surface-altering moieties and/or agents that can be employed in the invention include, but are not limited to, Hyaluronic acid, Carbomer, Polycarbophil, CMC-Na, Benzalkonium chloride, Cetalkonium chloride, Benzethonium chloride, Chitosan, Oleylamine, and Cetrimide. The zeta potential of a coated particle can be, for example, at least about - l OOmV, at least about -75m V, at least about - 50m V, at least about -30mV, at least about -20m V, at least about - l OmV, at least about -5mV, at least about 5mV, at least about l OmV, at least about 20m V, at least about 30m V, at least about 50m V, at least about 75mV, or at least about l OOmV. Preferably, the coated particle has a zeta potential in a range of about -30m V to 30m V, which is an optimal range of zeta potential for maintaining suspension stability. However, other ranges are also possible.
[0080] According to embodiments of the invention, a bioadhesive offers advantages such as localizing a dosage form within a particular region, increasing drug bioavailability, promoting contact with a surface for a longer time, and reducing dosage frequency. In certain instances, the bioadhesive can be biodegradable and/or biocompatible polymers which include, but are not limited to, hyaluronic acid (HA), derivatives of HA and salts of HA, such as cross-linked hyaluronic acid, sodium hyaluronate, and cationic derivative of HA; gelatin, chondroitin sulfate, collagen, cross-linked collagen, collagen derivatives (such as succinylated collagen or methylated collagen), chitosan, chitosan derivatives (such as methylpyrrolidone-chitosan), chitin and other glycosaminoglycans, stearylamine, oleylamine, polyethylenimine (PEI), poly-L-lysine (PLL), cationic lipids such as N-(l -(2,3-dioleoyloxy)propyl)-N,N,N trimethylammonium (DOTAP) chloride and dioleoyl phosphatidylethanolamine (DOPE), and quaternary ammonium compounds and their derivatives, or any suitable combination thereof.
[0081] The invention also relates to use of the ophthalmic formulations described herein to treat or prevent ocular disorders, and particularly ocular surface diseases. According to embodiments of the invention, a method of treating an ocular surface disease in a subject in need thereof comprises administering to an eye of the subject an ophthalmic formulation of the invention. Any of the ophthalmic formulations described herein can be used in a method of the invention. Preferably, an ophthalmic formulation of the invention is topically administered to the eye of the subject. It is believed that ophthalmic formulations of the invention have advantageous properties in terms of drug release, bioavailability, and/or compl iance in mammals that make them suitable for use in treating ocular disorders, such as ocular surface diseases.
[0082] As used herein, "subject" means any animal, preferably a mammal, most preferably a human, to whom will be or has been treated by a method according to an embodiment of the invention. The term "mammal" as used herein, encompasses any mammal. Examples of mammals include, but are not limited to, cows, horses, sheep, pigs, cats, dogs, mice, rats, rabbits, guinea pigs, non-human primates (NHPs) such as monkeys or apes, humans, etc.. and more preferably a human. [0083] An "ocular surface disease" as used herein refers to any disorder of the surface of the eye, which is the exposed layer that forms the front of the eye. Examples of ocular surface diseases that can be treated according to a method of the invention include, but are not limited to, angiogenesis in the front of the eye, such as corneal angiogenesis following e.g. keratitis, corneal transplantation, or keratoplasty; conj unctival degeneration (pinguecula) with slow proliferation; conjunctival papilloma, corneal angiogenesis due to hypoxia; hyperemia; hyperemia associated with pterygium; hyperthyroidism-induced eye congestion; immune or surgery related dry eyes; neovascular glaucoma (NVG); ocular cancer, pterygium conjunctivae; recurrent pterygium;
Steven Johnson syndrome; and stye.
[0084] In preferred embodiments of the invention, the ocular surface disease to be treated is hyperemia associated with pterygium, pterygium conjunctivae, recurrent pterygium, or corneal angiogenesis.
[0085] Ptergyium is a condition of the eye characterized by a vascular, pink, fleshy growth on the white of the eye originating from the conjunctiva, which can spread into the corneal limbus. The lesion can take any shape, but is typically triangular or wing-shaped. A pterygium lesion usually has three parts: a cap, a head, and a body/tail. The cap is a flat zone on the cornea containing mostly fibroblasts; the head is a vascular area behind the cap that is firm ly attached to the cornea; and the body/tail is the mobile area over the bulbar conjunctiva. Patients are typically asymptomatic until the lesion spreads into the cornea, where it can cause blurred vision. However, some patients do experience symptoms, such as burning, a gritty feeling in the eye, or a foreign body sensation early in the disease progression. Pterygium lesions can be primary lesions, or recurrent lesions. Recurrent lesions are lesions that return after removal of the initial primary lesion, such as by surgical removal. Recurrent pterygium refers to pterygium lesions that occur after an initial or primary lesion has already been removed or treated. Pterygium can also be associated with other conditions and side effects, such as hyperemia. Hyperemia (redness) generally refers to an increase in blood flow to the eye resulting in increased redness of the eye. Hyperemia can occur on its own (primary), or it can be a symptom associated with one or more other ocular diseases (secondary), such as pterygium.
[0086] In accordance with other embodiments of the invention, the ophthalmic
formulations comprising Nintedanib in a therapeutically effective amount may also be
administered for example, via intravitreal injection to the back/posterior of the eye, for the treatment of other ocular diseases characterized by neovascularization, vascular permeability, edema, or inflammation. These ocular diseases include but are not limited to ocular inflammation and/or ocular angiogenesis such as aged-related macular degeneration (AMD), proliferative and non-proliferative diabetic retinopathy, choroidal neovascularization, uveitis, rubeosis iridis, and neovascular glaucoma.
[0087] The terms "treat," "treating," and "treatment" as used herein refer to administering a composition to a subject to achieve a desired therapeutic or clinical outcome in the subject. In one embodiment, the terms "treat," "treating," and "treatment" refer to administering an ophthalmic formulation of the invention to reduce, alleviate or slow the progression or
development of an ocular surface disease. In yet another embodiment, the terms "treat," "treating," and "treatment" refer to administering an ophthalmic formulation of the invention to inhibit or reduce corneal neovascularization and/or cell proliferation in the eye. In yet another embodiment, the terms "treat," "treating," and "treatment" refer to administering an ophthalmic formulation of the invention to slow the progression or development of new blood vessels in the cornea (i.e., corneal neovascularization).
[0088] In particular embodiments of the invention, when used with reference to pterygium, the terms "treat," "treating," and "treatment" refer to preventing the growth of recurrent lesions or reducing the recurrence rate of such lesions; slowing, delaying, or preventing the spread of lesions from the conjunctiva into the corneal region; reducing or alleviating one or more symptoms associated with pterygium, such as a burning sensation or gritty feeling in the eye; regression of lesion from the corneal region; and/or reducing, slowing the progression of, or alleviating secondary conditions associated with pterygium, such as hyperemia.
[0089] According to embodiments of the invention, an ophthalmic formulation can be administered by any method known to those skilled in the art in view of the present disclosure, such as by topical administration, subconjunctival injection, or ophthalmic delivery by a device such as contact lens. In a preferred embodiment, the ophthalmic formulation is topically administered, e.g., by eye drops or by swabbing, insertion of a contact lens loaded with the drug, or an erodible or non-erodible insert placed in the cul-de-sac of the eye. For example, a liquid nanosuspension can be administered as eye drops. Nanoparticles in the form of eye drops can quickly access and associate with the cornea and conjunctiva, and those nanoparticles residing on the cornea and conjunctiva can contribute to drug levels predominantly in the ocular tissues of the anterior segment of the eye. An ophthalmic formulation can be administered to any part of the eye, and is preferably administered to the surface of the eye for the treatment of an ocular surface disease.
[0090] Parameters such as the dosage amount, frequency of administration, and duration of administration of an ophthalmic formulation to a subject according to an embodiment of the invention are not limited in any particular way. The optimum values of such parameters can depend on a variety of factors, such as the subject to be treated, the particular ocular surface disease to be treated, the severity of the disease, etc., and one of ordinary skill in the art will be able to determine the optimum values for such parameters in order to achieve the desired therapeutic or clinical outcome. For example, an ophthalmic formulation can be administered once per day, or more than once per day, such as twice, three times, four times, etc. An exemplary and non-limiting dosing regimen comprises administering an ophthalmic formulation as eye drops three times per day for a duration of one to two weeks.
[0091] The invention also relates to a method of preparing an ophthalmic formulation, including a method of preparing any of the ophthalmic formulations described herein. According to embodiments of the invention, a method of preparing an ophthalmic formulation comprises optionally forming nanoparticles or microparticles of a tyrosine kinase inhibitor selected from the group consisting of Axitinib, Nintedanib, Sorafenib, Pazopanib, prodrugs thereof, and
pharmaceutically acceptable salts thereof, and combining the tyrosine kinase inhibitor, or microparticles or nanoparticles thereof with at least one pharmaceutically acceptable excipient.
[0092] According to embodiments of the invention, the nanoparticles or microparticles can be formed in the presence of surfactant. Any of the surfactants described herein can be used including, but not limited to, Tween 80, Tween 20, poloxamer 1 88, poloxamer 407, or tyloxapol, and preferably tyloxapol. Any of the methods described herein can be used to form the nanoparticles or microparticles. Preferably, milling is used, such as a ball-milling process.
[0093] The following examples of the invention are to further illustrate the nature of the invention. It should be understood that the following examples do not limit the invention and that the scope of the invention is to be determined by the appended claims.
EMBODIMENTS
[0094] Embodiment 1 is an ophthalmic formulation comprising a therapeutically effective amount of Nintedanib, a prodrug thereof, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.
[0095] Embodiment 2 is the ophthalmic formulation of embodiment 1 , wherein the at least one pharmaceutically acceptable excipient is selected from the group consisting of surfactants, preservatives, viscosity regulators, pH-adjusting agents, stabilizers, and osmo-regulators.
[0096] Embodiment 3 is the ophthalmic formulation of embodiment 2, wherein the surfactant is selected from the group consisting of Tween 80, Tween 20, Poloxamer 188, poloxamer 407 and Tyloxapol. [0097] Embodiment 4 is the ophthalmic formulation of embodiment 3, wherein the surfactant is Tyloxapol.
[0098] Embodiment 5 is the ophthalmic formulation of embodiment 2, wherein the viscosity regulator is selected from the group consisting of HPMC, Sodium
Carboxymethylcellulose, Carbomer, Polycarbophil, PEG and HA or its salts and derivatives.
[0099] Embodiment 6 is the ophthalmic formulation according to any one of embodiments
1 to 5, wherein the ophthalmic formulation comprises micronized particles or nanonized particles of Nintedanib, the prodrug thereof, or the pharmaceutically acceptable salt thereof.
[0100] Embodiment 7 is the ophthalmic formulation according to any one of embodiments 1 to 6, wherein the formulation is a liquid suspension, preferably a nanosuspension, for topical ocular administration.
[0101] Embodiment 8 is the ophthalmic formulation according to any one of embodiments 1 to 7, wherein a concentration of Nintedanib, the prodrug thereof, or pharmaceutically acceptable salt thereof is 0.01 % to 10% vv/v.
[0102] Embodiment 9 is an ophthalmic formulation comprising a therapeutically effective amount of micronized or nanonized particles comprising a tyrosine kinase inhibitor selected from the group consisting of Axitinib, Nintedanib, Sorafenib, Pazopanib, a prodrug thereof, and a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.
[0103] Embodiment 10 is the ophthalmic formulation of embodiment 9, wherein a
concentration of the tyrosine kinase inhibitor is 0.01 % to 10% w/v.
[0104] Embodiment 1 1 is the ophthalmic formulation according to embodiment 9 or embodiment 10, wherein the formulation is a liquid suspension, preferably a nanosuspension, for topical ocular administration.
[0105] Embodiment 12 is a method of treating an ocular surface disease in a subject in need thereof, the method comprising administering to an eye of the subject the ophthalmic formulation according to any one of embodiments 1 to 1 1.
[0106] Embodiment 13 is the method of embodiment 12, wherein the ocular surface disease is selected from the group consisting of angiogenesis in the front of the eye; corneal angiogenesis following keratitis, corneal transplantation, or keratoplasty; conjunctival degeneration (pinguecula) with slow proliferation; conjunctival papilloma; corneal angiogenesis due to hypoxia; hyperemia; hyperemia associated with pterygium; hyperthyroidism-induced eye congestion; dry eyes
(including but not limited to immune-related, inflammation-related or surgery-related);
neovascular glaucoma (NVG); ocular cancer; pterygium conjunctivae; recurrent pterygium;
Steven Johnson syndrome; and stye. [0107] Embodiment 14 is the method of embodiment 1 3, wherein the ocular surface disease is hyperemia associated with pterygium, pterygium conjunctivae, or recurrent pterygium.
[0108] Embodiment 1 5 is a method of preparing the ophthalmic formulation of any one of embodiments 1 to 1 1 , comprising optionally forming microparticles or nanoparticles comprising a tyrosine kinase inhibitor selected from the group consisting of Axitinib, Nintedanib, Sorafenib, Pazopanib, a prodrug thereof, and a pharmaceutically acceptable salt thereof, and m ixing the tyrosine kinase inhibitor or the nanoparticles or microparticles thereof with at least one pharmaceutical ly acceptable excipient.
[0109] Embodiment 16 is the method of embodiment 15, wherein the m icroparticles or nanoparticles are formed by a milling process.
[0110] Embodiment 17 is the method of embodiment 15 or embodiment 16, wherein the m icroparticles or nanoparticles are formed in the presence of tyloxapol.
[0111] Embodiment 1 8 is the ophthalmic formulation of any one of embodiments 9 to 1 1 , wherein the nanoparticles have a D90 particle size of less than 1 μηι.
[0112] Embodiment 19 is use of the ophthalm ic form ulation of any one of embodiments 1 to
1 1 in the preparation of a medicament for treating an ocular surface disease.
[0113] Embodiment 20 is the ophthalmic formulation of any one of embodiments 1 to 1 1 for use in treating an ocular surface disease.
[0114] Embodiment 21 is N intedanib, a prodrug thereof, or a pharmaceutically acceptable salt thereof for use in treating an ocular surface disease.
[0115] Embodiment 22 is use of Nintedanib, prodrug thereof, or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating an ocular surface disease.
[0116] Embodiment 23 is an ophthalmic formulation comprising:
(a) a therapeutically effective amount of nanoparticles comprising Nintedanib or a pharmaceutically acceptable salt thereof in a concentration of about 0. 1 % w/v to about 10% w/v;
(b) about 0.01 % to 0.3% tyloxapol; and
(c) about 0. 1 % to 1 % HPMC.
wherein the formulation is a liquid suspension for topical administration.
[0117] Embodiment 24 is the ophthalmic formulation of embodiment 23 having a D| 0 particle size in a range of about 0.1 -0.5 μιη.
[0118] Embodiment 25 is the ophthalmic formulation of embodiment 23 or embodiment 24 having a D5o particle size in a range of about 0.4- 1 .5 μιη.
[0119] Embodiment 26 is the ophthalmic formulation of any one of embodiments 23 to 25 having a D90 particle size in a range of about 0.5-3.0 μιτι. [0120] Embodiment 27 is a method of treating an ocular surface disease in a subject in need thereof, the method comprising administering to an eye of the subject the ophthalmic formulation according to any one of embodiments 23 to 26.
[0121] Embodiment 28 is the method of embodiment 27, wherein the ocular surface disease is selected from the group consisting of angiogenesis in the front of the eye; corneal angiogenesis following keratitis, corneal transplantation, or keratoplasty; conjunctival degeneration (pinguecula) with slow proliferation; conjunctival papilloma; corneal angiogenesis due to hypoxia; hyperemia; hyperemia associated with pterygium; hyperthyroidism-induced eye congestion; dry eyes
(including but not limited to immune-related, inflammation-related or surgery-related);
neovascular glaucoma (NVG); ocular cancer; pterygium conjunctivae; recurrent pterygium;
Steven Johnson syndrome; and stye.
[0122] Embodiment 29 is the method of embodiment 28, wherein the ocular surface disease is hyperemia associated with pterygium, pterygium conjunctivae, recurrent pterygium, or corneal angiogenesis.
EXAMPLES
[0123] Example 1 : Preparation of Ophthalmic Suspension Containing Nintedanib Ethanesulfonate
[0124] A 0.3% Nintedanib Ethanesulfonate ophthalmic suspension having the components listed in Table 1 below was prepared.
Table 1
Figure imgf000022_0001
[0125] Vehicle Preparation [0126] First, 2% hydroxypropyl methylcellulose (HPMC) stock and 5X buffer preparation were mixed, followed by addition of a sufficient quantity (QS) of purified water to obtain a vehicle having a final concentration of 1 % HPMC stock and 20% buffer for formulating the ophthalmic liquid suspension. The HPMC stock and buffer preparation were prepared as follows.
[0127] HPMC Stock (2%)
For the preparation of 200 mL HPMC, the following procedure was followed:
( 1 ) Water ( 150 mL) was heated to about 80°C (under continuous stirring);
(2) HPMC (4 g) was gradually added to the water (under constant stirring) to form an HPMC solution;
(3) The HPMC solution was mixed until it was well dispersed and suspended;
(4) The HPMC solution was quantitatively transferred to a 200 mL volumetric flask and purified water was added to near final volume;
(5) The volumetric flask was placed in a water bath under constant stirring to cool to room temperature; and
(6) Purified water was added to a final volume of 200 mL, and mixed well.
[0128] Buffer Preparation (5X)
For the preparation of 200 mL of 5X buffer, the following procedure was followed:
( 1 ) Sodium Phosphate Dibasic Heptahydrate (2.7 mg), Sodium Phosphate
Monobasic Monohydrate (0.3 g), Sodium Chloride (8.5 g), Edetate Disodium ( 1 .0 g), Polysorbate 80 (1.0 g), and Benzalkonium Chloride (0.050 g) were dissolved in 180 mL of purified water;
(2) The pH was adjusted to 7.4 with 1 N NaOH;
(3) The buffer was transferred to a 200 mL volumetric flask; and
(4) Purified water was added to a final volume of 200 mL, and the buffer was mixed well.
[0129] Preparation of Liquid Suspension
[0130] Next, the liquid suspension of Nintedanib Ethanesulfonate (0.3% w/vv) was prepared in accordance with the following procedure:
( 1) Nintedanib Ethanesulfonate (45.37 mg) and vehicle (14.9751 5 g) were weighed into a 20 mL scintillation vial, a stir bar was added, and the vial was securely capped;
(2) The vial was swirled with sonication for about 1 minute;
(3) The vial was shaken for about 30 seconds to disperse large API aggregates;
(4) The vial was swirled with sonication for about 1 minute; (5) The vial was mixed on magnetic stir plate at high speed for 5 minutes;
(6) Steps (3)-(5) were repeated as needed, until Nintedanib Ethanesulfonate was uniformly dispersed/suspended and no visible aggregate remained (estimated total mixing and sonication time was about 1 .25 hours);
(7) The vial was mixed on the magnetic stirrer for an additional 10 minutes to obtain an ophthalmic liquid suspension containing 0.3% Nintedanib
Ethanesulfonate.
[0131] Suspension Uniformity Testing
[0132] Suspension uniformity for the 0.3% Nintedanib Ethanesulfonate liquid suspension was determined by using a high performance liquid chromatography (HPLC) method in accordance with the following setup and preparations.
[0133] Instrument Setup: The HPLC method was performed using an instrument with the parameters set as shown in Table 2.
Table 2
Figure imgf000024_0001
[0134] Diluent Preparation: Water and methanol were mixed in a 1 : 1 ratio by volume to prepare the diluent. For the preparation of 1 L of diluent, 500 mL water was mixed with 500 mL of methanol.
[0135] Vehicle Preparation: Vehicle (0.5 g) was diluted in 25 mL diluent and mixed well.
[0136] Nintedanib Ethanesulfonate Standard Preparation: Nintedanib Ethanesulfonate (50.33 mg) was weighed into a 50 mL volumetric flask, diluent was added (40 mL), and the mixture was sonicated to dissolve. The mixture was diluted with diluent to obtain a standard stock solution of 1 .0066 mg/mL of Nintedanib Ethanesulfonate. The standard stock solution was further diluted with diluent and mixed well to obtain a standard preparation of 0.0604 mg/mL of Nintedanib Ethanesulfonate.
[0137] Sample Preparation: The 0.3% Nintedanib Ethanesulfonate liquid suspension (0.5 g) was weighed into a 25 mL volumetric flask, diluted with diluent (20 mL), and mixed and sonicated to dissolve. The mixture was further diluted with diluent and mixed well to obtain a sample preparation containing 0.060 mg/mL of Nintedanib Ethanesulfonate.
[0138] Samples from top, middle, and bottom locations of the scintillation vial were taken immediately after the suspension was prepared, after 8 hours at room temperature (bench top under constant mix), and after sitting at room temperature for 1 hour with no mixing. The samples were analyzed by HPLC. A total of nine samples were tested.
[0139] The results of suspension uniformity testing assay for the 0.3% Nintedanib
Ethanesulfonate suspension showed good suspension uniformity at all time points and for all locations in the vial, with an overall % relative standard deviation (% RSD) of the nine samples tested of less than 2%.
[0140] Particle Size Distribution Analysis
[0141] Particle size analysis of the 0.3% Nintedanib Ethanesulfonate ophthalmic liquid suspension was performed in triplicate using a Laser Scattering Particle Size Distribution Analyzer LA-950. A summary of the results is shown in Table 3.
Table 3
Figure imgf000025_0001
[0142] The results of the particle size distribution analysis testing show that the average particle diameter of the 0.3%o Nintedanib Ethanesulfonate suspension prepared as described above is in the micrometer range.
[0143] Osmolality and pH
[0144] The osmolality of the 0.3% Nintedanib Ethanesulfonate suspension was tested in triplicate and found to be 325 mOsm/kg (n=3). The pH was measured to be 7. 18.
[0145] Example 2: Preparation of Ophthalmic Suspension Containing Axitinib
[0146] A 1 % (w/w) Axitinib ophthalmic formulation was prepared as a liquid suspension.
The components of the Axitinib liquid suspension are the same as shown in Table 1 , except the suspension contained 1 % Axitinib rather than 0.3% Nintedanib Ethanesulfonate. The vehicle was also prepared as described above in Example 1.
[0147] The Axitinib ophthalmic suspension was prepared according to the following procedure: ( 1 ) Axitinib ( 150.24 mg) and vehicle ( 14.8225 g) were weighed into a 20 mL scintillation vial, a stir bar was added, and the vial was securely capped;
(2) The vial was swirled with sonication for about 2 minutes;
(3) The vial was shaken to disperse large aggregates of Axitinib for about 30 seconds;
(4) The vial was sonicated and swirled intermittently for 1 minute;
(5) The vial was mixed on a magnetic stir plate at high speed for 5 minutes:
(6) Steps (3)-(5) were repeated as needed, until Axitinib was uniformly
dispersed/suspended and no visible aggregate remained (estimated total mixing and sonication time is about 0.5 hours).
(7) The vial was mixed on the magnetic stirrer for an additional 10 minutes to obtain an ophthalmic liquid suspension containing 1 % Axitinib.
[0148] Suspension Uniformity Testing
[0149] The suspension uniformity for 1 % Axitinib was determined using a high performance liquid chromatography (HPLC) method in accordance with the following setup and preparations.
[0150] Instrument Setup: The HPLC method was performed using an instrument with the parameters set as shown in Table 4.
Table 4
Figure imgf000026_0001
[0151] Diluent Preparation: For the preparation of 1 L of diluent, 650 mL of 0.1 % H3PO4 (-85%) was mixed with 350 mL of water.
[0152] Vehicle Preparation: Vehicle (0.5 g, prepared as described in Example 1 ) was diluted in 25 mL of diluent and mixed well. [0153] Standard Preparation of Axitinib; Axitinib (51 .1 2 mg) was mixed with di luent (40 mL) and sonicated to dissolve. The m ixture was further diluted with diluent to obtain a standard preparation having a final concentration of 0.2045 mg/mL of Axitinib.
[0154] Sample Preparation: The 1 % Axitinib suspension preparation (0.5 g) was weighed out, mixed with diluent (20 mL), and sonicated to dissolve. The m ixture was further diluted with diluent and mixed well to obtain sample preparations having a final concentration of about 0.2 mg/mL of Axitinib.
[0155] Samples from top, middle, and bottom locations of the scinti llation vial were taken immediately after the suspension was prepared, after 8 hours at room temperature (bench top under constant mix), and after sitting at room temperature for 1 hour with no mixing. The samples were analyzed by HPLC. A total of nine samples were tested.
[0156] The results of suspension uniform ity testing assay for the 1 % Axitinib suspension showed good suspension uni form ity at all time points and for al l locations in the vial, with an overal l % relative standard deviation (% RSD) of the nine samples tested of less than 2%.
[0157] Particle Size Distribution Analysis
[0158] Particle size analysis of the 1 % Axitinib ophthalmic l iquid suspension was performed in tripl icate using a Laser Scattering Particle Size Distribution Analyzer LA-950. A summary of the results is shown in Table 5.
Table 5
Figure imgf000027_0001
[0159] The results of the particle size distribution analysis testing show that the average particle diameter of the 1 % Axitinib suspension prepared as described above is in the micrometer range. In particular, the ophthalmic suspension has a Di o particle size of about 1 .6 μηι, a D5o of about 4.0 μιη and a D% of about 8.0 μιη.
[0160] Osmolality and pH
[0161 ] The osmolality of the 1 % Axitinib suspension was tested in tripl icate and found to be 307 mOsm/kg (n=3). The pH was measured to be 7.83.
[0162] Example 3: Ocular Tolerability Study of the Ophthalmic Suspension
[0163 ] The ocular tolerabi lity was evaluated, and ocular exposure was characterized after a single bilateral (both eyes) topical administration to male Dutch Belted rabbits (3 to 4 months old) having no visible signs of ocular defects. All animals received a topical administration in both eyes of either 0.3% Nintedanib Ethanesulfonate microsuspension, 0.3% Sorafenib Tosylate microsuspension, or 0.3% Axitinib microsuspension. The ophthalmic suspension containing Sorafenib Tosylate was prepared in the same manner as the Nintedanib Ethanesulfonate microsuspension and Axitinib microsuspension as described in Examples 1 and 2, respectively. All groups were dosed three times daily (TID) on Day 1 , 2, 3, and once on Day 4. A calibrated positive displacement pipette was used to administer a dose volume of 35 μΕ/eye onto the globe of each eye.
[0164] Clinical observations were conducted at receipt, prior to dosing, and prior to euthanasia. Tolerability assessments were conducted following each dose. Ocular irritation measurements, using the Draize scoring system, were conducted on Day 0 (predose), following the first dose of the day on Days 1 and 3, and immediately prior to the terminal time point on Day 4.
[0165] Draize scoring was 0 for all observations during the course of the study, which was in agreement with the daily observations. None of the formulations tested resulted in any extended ocular irritation.
[0166] At approximately 2 hours post the final dose on Day 4, rabbits were euthanized via barbiturate overdose prior to both eyes being harvested and dissected for collection of aqueous humor, conjunctiva, and cornea. Following collection, tissues were weighed and snap-frozen on dry ice, and placed in a freezer at -80°C until processed for analysis. Concentrations of
Nintedanib Ethanesulfonate, Sorafenib Tosylate, and Axitinib were quantitated using a qualified LC-MS/MS method in the conjunctiva, cornea, and aqueous humor collected following the terminal time point. The results are shown below in Table 6.
Table 6: Mean concentrations of Nintedanib Ethanesulfonate, Sorafenib Tosylate, and Axitinib measured in the conjunctiva, cornea, and aqueous humor.
Figure imgf000028_0001
ng/g= nanograms of Axitinib, N intedanib Ethanesulfonate, or Sorafenib Tosylate per gram of conjunctival tissue 2 ng/g= nanograms of Axitinib, Nintedanib Ethanesulfonate, or Sorafenib Tosylate per gram of corneal tissue
[0167] In the conjunctiva and cornea, the highest concentrations observed were quantitated as 5260 ng/g and 3910 ng/g respectively, following the administration of ophthalmic suspension containing 0.3% (w/w) Nintedanib Ethanesulfonate. In aqueous humor, the highest concentration of 15.4 ng/mL was quantitated following the dose of 0.3% (w/w) Axitinib.
[0168] In summary, all test compounds were well tolerated following topical ocular TID dosing for 3 days. With respect to tissue concentrations, topical ocular dosing with 0.3% (w/w) Nintedanib Ethanesulfonate resulted in the highest conjunctiva and cornea concentration, and 0.3% Axitinib (w/w) the highest aqueous humor concentration.
[0169] Example 4: Topical Efficacy of an Ophthalmic Suspension in an Animal Model of Cornea Suture-Induced Neovascularization
[0170] The aim of this study is to determine whether topical administration (eye drops) of ophthalmic suspensions of the invention result in decreased neovascularization in a rabbit model of cornea suture-induced neovascularization (Campos-Mollo et al., "New Corneal
Neovascularization Model in Rabbits for Angiogenesis Researc 'Op thcdmic Res. (2010) 45, 135- 141 ).
[0171 ] For this study, New Zealand white rabbits at approximately 5 months old with no visible signs of ocular defects were selected. Suture placement was performed on Day 1 . Prior to surgery, the right eye of each animal was dilated using a mydriatic agent ( 1 % tropicamide), and the conjunctiva was flushed with approximately 10 mL benzalkonium chloride (Zephiran™) diluted in sterile water, U.S. P. to 1 : 10,000 (v/v). Saline (0.9%) was also used to flush the eye along with benzalkonium chloride. Animals were anesthetized with isoflurane/oxygen during the procedure. Hydration of the eyes was maintained by irrigation with saline solution, as needed. The procedure was conducted under a dissecting or surgical microscope. The cornea of the right eye was exposed using an eyelid speculum. The central corneal area was appropriately marked as considered necessary by the surgeon. In the right eye of each animal, one 9.0 silk suture was placed intrastromally, approximately 1 mm from the limbus with 2 stromal incursions. The outer point of suture placement was chosen near the limbus ( 1 -2 mm), and the inner suture point was chosen near the corneal center, equidistant from the limbus, to obtain standardized angiogenic responses. The left eye remained untreated.
[0172J The study design is shown below in Table 7:
Table 7
Figure imgf000029_0001
(males)
Suspension 0 35 0 Topical 6
Vehicle
Avastin 5 mg/eye 200 25 Subconjunctival 6
(active control)
Axitinib' 0.3% 35 3 Topical 6
Nintedanib 0.3% 35 3 Topical 6
Ethanesulfonate 1
Sorafenib 0.3% 35 3 Topical 6
Tosylate1
Formulations were liquid microsuspensions
[0173] Dose formulations were administered by subconjunctival injection to the sutured right eye of each animal of the Avastin control group (5 mg) on Days 1 and 7, at a dose volume of 200 ^iL/dose immediately post suture placement. Dose formulations were given three times daily (TID) for the group administered with suspension vehicle, 0.3% Axitinib, 0.3% Nintedanib
Ethanesulfonate, or 0.3% Sorafenib Tosylate for a duration of 14 days. Dose formulations were administered 6 hours apart ± 30 minutes by topical ocular instillation (onto the superior corneal surface) to the right eye using a calibrated positive displacement micropipette, to ensure contact with the conjunctiva. The dosing volume was one 35 μΙ_. drop per dose. After the dose was administered, the upper and lower eyelids were gently held together to prevent the loss of material and to distribute the dose across the eye.
[0174] Ocular imaging and neovascularization assessments were performed once pre- treatment, and also once on Days 7 and 14. A pre-anesthetic cocktail of Ketamine ( 1 5 mg/kg) and Dexmedetomidine (0.25 mg/kg) was administered subcutaneously, and the animals were maintained with isoflurane/oxygen mix prior to and during the procedure. Still images of the cornea were taken from both eyes (from the center of each eye, nasally and temporally). Images were evaluated qualitatively and quantitatively to assess the degree of corneal neovascularization (CNV), and to determine the area affected by CNV. The length of the vessel incursion was measured from the limbus to the distal end of the encroaching CNV using a digital micrometer (in millimeters) for each selected image. Qualitative assessments included the percentage estimate of involved corneal circumference (using multiple images as necessary), and vessel branching.
[0175] CNV was noted on Days 7 and 14 in the right eyes of animals given the suspension vehicle averaging I to 2.7 mm in length and affecting up to 50% of the corneal circumference, with slight to moderate branching of the vessels (see Figures 1 A and I B). In contrast, minimal to no CNV was noted in some animals given 5 mg Avastin/eye (see Figures 2A and 2B). Notably, animals treated with Avastin were observed to have minimal CNV on Day 14 (-0.5 to 1.1 mm), encompassing between 20 to 30% of the corneal circumference (Figure 2B). [0176] On Day 7, CNV was not observed in animals given Axitinib or Nintedanib
Ethanesulfonate (see Figure 3A and Figure 4A). In these groups, vessels were approximately 0.5 mm in length, which covered approximate 20% of the corneal circumference and had very slight to moderate vessel branching. The group treated with Nintedanib Ethanesulfonate was considered comparable to one given Avastin at Day 7. By Day 14, the vessels were characterized as sparse and no branching was observed in the group administered with Nintedanib Ethanesulfonate (Figure 4B). At Day 15, the group given Nintedanib Ethanesulfonate was considered slightly more efficacious compared to the one given Avastin when comparing vessel length, surface area and vessel branching. Slight corneal neovascularization was observed for animals treated with Sorafenib Tosylate on both Day 7 and Day 14 (Figure 5A and Figure 5B) compared with the Avastin control group, with CNV length and area increasing by Day 14. The results are also summarized below in Table 8.
Table 8: Summary of Corneal Neovascularization (CNV) Assessments
Figure imgf000031_0001
0=none, l =very slight; 2=slight; 3=moderate; 4=severe.
[0177] Over the course of the study, no treatment-related clinical signs were observed. Few ocular-related clinical signs were observed, such as eye discharge, partially closed eyes, and redness, but the observation of these instances appeared to be sporadic with no particular relation to the treatment.
[0178] The results of the above study demonstrate that ophthalmic suspension formulations containing Nintedanib Ethanesulfonate and Axitinib were both well-tolerated and efficacious in preventing or slowing CNV progression. The results also demonstrate that Nintedanib
Ethanesulfonate was more efficacious, or at least comparable to Avastin in preventing or slowing CNV progression.
[0179] Example 5: Preparation of Ophthalmic Nanosuspensions Containing Nintedanib
[0180] Ophthalmic formulations in the form of liquid suspensions containing nanoparticles of Nintedanib were prepared. [0181] Nintedanib (4.0 g) was dispersed and mixed by stirring in 200 ml 0.2% Tyloxapol solution at the room temperature. Next, the mixture of Nintedanib and Tyloxapol was milled in the 160 mL chamber of a NETZSCH® MINICER along with 200 μιτι zirconium oxide grinding beads. The milling speed and time was adjusted to alter certain properties of the formulation composition, such as particle size distribution. An exemplary speed and time used was 3000 rpm for 20 minutes. Following milling, the particle size distribution of the Nintedanib particles was evaluated. The particle size distribution and composition of an exemplary Nintedanib nanosuspension made according to the ball-milling process described above is shown in Table 9.
Table 9: 1 % Nintedanib Ophthalmic Nanosuspension
Figure imgf000032_0001
[0182] Chemical Stability Testing
[0183] Chemical stability as well as formulation stability of nanosuspensions are important to maintain formulation characteristics and the desired pharmacological effects. The
nanosuspensions were monitored at varying storage conditions, including different storage times and storage temperatures. In particular, the nanosuspensions were tested after 20 days and 30 days after storage at room temperature, 40°C, or 60°C. Some impurities were detected in all samples tested, after storage for 20 days and 30 days at room temperature, 40°C and 60 °C similar to the initial test value.
[0184] Effect of Surfactants on Particle Size
[0185] Various surfactants including Tween 80, Tvveen 20, Poloxamer 188 (Pluronic® F-68), and Tyloxapol were also tested for their wetting ability in the ball-milling process. According to the results shown in Table 10, including Tyloxapol in the nanosuspension reduces the D90 particle size down into the nanometer range, i.e., below 1 μιη, as compared to the other surfactants tested in which the D90 particle size was greater than 1 μιη. The effect of the surfactants on stability in
3 terms of particle size of the nanosiispensions was also evaluated after storage at 20 days and 30 days at room temperature, 40°C, or 60°C. The results are shown in Table 10.
[0186]
Table 10
Figure imgf000033_0001
0187] As shown in Table 10 above, formulation 4 containing Tyloxapol in particular showed little or no increase in the particle size after storage for 20 days and 30 days at all temperatures tested.
[0188] Effect of Suspending Agent on Particle Size Stability in Nanosuspensions
[0189] The effects of polymers, including carboxymethylcellulose sodium (CMC-Na 7L2P, W 49000) and hydroxylpropyl methylcellulose (HPMC E4M, MW 86000) as suspending agents, on particle size stability in nanosuspensions were evaluated. The particle size of the
nanosuspensions was measured after storage for 7 days, 14 days, and 28 days at 4°C, room temperature, 40°C, and 60°C. As shown in Table 1 1 below, little to no increase in the particle size was found in nanosuspensions containing HPMC (Formulation 1 ).
Table 11 :
Figure imgf000033_0002
Initial 0.274/0.450/0.813 0.254/0.418/0.930
60 °C 7 days 0.255/0.420/0.895 0.268/0.453/1.31
14 days 0.250/0.408/0.900 0.305/0.559/2.14
28 days 0.255/0.425/1.06 0.291/0.53 1/2.33
40 °C 14 days 0.249/0.391 /0.672 0.282/0.493/1.26
28 days 0.247/0.388/0.670 0.294/0.506/1.67
RT 14 days 0.256/0.408/0.709 0.280/0.480/1.08
30 days 0.254/0.421/1.04 0.303/0.582/2.80
4 °C 30 days 0.246/0.385/0.667 0.282/0.482/1.12
[0190] Effect of pH on Particle Size Stability in Nanosuspensions
[0191] Aqueous solubility of Nintedanib varies with the pH value of the formulation, which can lead to subsequent changes in particle size. Therefore, the particle size stability of nanosuspensions with varying pH values was evaluated. The pH of the formulation was adjusted to the indicated value prior to measuring the particle size of the initial suspension. The results for formulations with pH values of 5.8, 6.5, 7.0, and 7.4 are reported in Table 12.
Table 12
Figure imgf000034_0001
a = abnormal data
[0192] The results show that at pH values higher than 5.8, such as pH 6.5, 7.0, and 7.4, the particle size remained relatively stable after 28 days. [0193] Homogeneity of Nanosuspensions
[0194] To determine the homogeneity of nanosuspensions, nintedanib nanosuspensions containing various surfactants or at different pH as l isted in Table 13 below were allowed to sit for 1 hour, followed by shaking 10 times by hand (amplitude; 10 cm), After shaking, samples were taken from top, midd le, and bottom parts of the nanosuspensions and analyzed for Nintedanib content. The results, reported in Table 13 as "Homogeneity at 1 Hour," showed good suspension homogeneity after re-suspension.
Table 13
Figure imgf000035_0001
[0195] Wh ile the invention has been described in detail, and with reference to specific embodiments thereof, it wil l be apparent to one of ordinary skill in the art that various changes and modifications can be made therein without departing from the spirit and scope of the invention.

Claims

CLAIMS We claim:
1. An ophthalmic formulation comprising a therapeutically effective amount of Nintedanib, a prodrug thereof, or a pharmaceutically acceptable salt thereof, and at least one
pharmaceutically acceptable excipient.
2. The ophthalmic formulation of claim 1 , wherein the at least one pharmaceutically acceptable excipient is selected from the group consisting of surfactants, preservatives, viscosity regulators, pH-adjusting agents, stabilizers, and osmo-regulators.
3. The ophthalmic formulation of claim 2, wherein the surfactant is selected from the group consisting of Tween 80, Tween 20, Polysorbate, Poloxamer, and Tyloxapol.
4. The ophthalmic formulation of claim 3, wherein the surfactant is Tyloxapol.
5. The ophthalmic formulation of claim 2, wherein the viscosity regulator is selected from the group consisting of Hydroxypropyl Methylcellulose (HPMC), Sodium
Carboxymethylcellulose, Carbomer, Polycarbophil, Polyoxyethylene glycol (PEG), and Hyaluronic Acid (HA).
6. The ophthalmic formulation according to any one of claims 1 to 5, wherein the ophthalmic formulation comprises micronized particles or nanonized particles comprising Nintedanib, a prodrug thereof , or a pharmaceutically acceptable salt thereof.
7. The ophthalmic formulation according to any one of claims 1 to 6, wherein the formulation is a liquid suspension for topical ocular administration.
8. The ophthalmic formulation according to any one of claims 1 to 7, wherein a concentration of Nintedanib, the prodrug thereof, or pharmaceutically acceptable salt thereof is 0.01 % to 10% w/v.
9. An ophthalmic formulation comprising a therapeutically effective amount of nanonized
particles comprising a tyrosine kinase inhibitor selected from the group consisting of Axitinib,
Nintedanib, Sorafenib, Pazopanib, a prodrug thereof, and a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.
10. The ophthalmic formulation of claim 9, wherein a concentration of the tyrosine kinase
inhibitor is 0.01 % to 10% w/v.
1 1. The ophthalmic formulation according to claim 9 or claim 10, wherein the formulation is a liquid suspension for topical ocular administration.
12. A method of treating an ocular surface disease in a subject in need thereof, the method
comprising administering to an eye of the subject the ophthalmic formulation according to any one of claims 1 to 1 1. The method of claim 12, wherein the ocular surface disease is selected from the group consisting of angiogenesis in the front of the eye; corneal angiogenesis following keratitis, corneal transplantation, or keratoplasty; conjunctival degeneration (pinguecula) with slow proliferation; conjunctival papilloma; corneal angiogenesis due to hypoxia; hyperemia;
hyperemia associated with pterygium; hyperthyroidism-induced eye congestion; dry eyes; intraretinal edema; macular edema; macular edema due to retinal vein occlusion; neovascular glaucoma (NVG); ocular cancer; pterygium conjunctivae; recurrent pterygium; Steven
Johnson syndrome; stye; and subretinal edema.
The method of claim 13, wherein the ocular surface disease is hyperemia associated with pterygium, pterygium conjunctivae, recurrent pterygium or corneal angiogenesis.
A method of preparing the ophthalmic formulation of any one of claims 1 to 1 1 , comprising optionally forming nanoparticles or microparticles of a tyrosine kinase inhibitor selected from the group consisting of Axitinib, Nintedanib, Sorafenib, Pazopanib, a prodrug thereof, and a pharmaceutically acceptable salt thereof, and combining the tyrosine kinase inhibitor, or microparticles or nanoparticles thereof with at least one pharmaceutically acceptable excipient.
PCT/US2016/034822 2015-06-22 2016-05-27 Ophthalmic formulations of tyrosine kinase inhibitors, methods of use thereof, and preparation methods thereof WO2016209555A1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
KR1020207003834A KR102096296B1 (en) 2015-06-22 2016-05-27 Ophthalmic formulations of tyrosine kinase inhibitors, methods of use thereof, and preparation methods thereof
MX2017016655A MX2017016655A (en) 2015-06-22 2016-05-27 Ophthalmic formulations of tyrosine kinase inhibitors, methods of use thereof, and preparation methods thereof.
KR1020177034479A KR20170140399A (en) 2015-06-22 2016-05-27 Ophthalmic formulations of tyrosine kinase inhibitors, methods of use thereof and methods of making the same
EP16814997.9A EP3310339A4 (en) 2015-06-22 2016-05-27 Ophthalmic formulations of tyrosine kinase inhibitors, methods of use thereof, and preparation methods thereof
BR112017025757-2A BR112017025757B1 (en) 2015-06-22 2016-05-27 OPHTHALMIC FORMULATIONS OF TYROSINE KINASE INHIBITORS AND THEIR PHARMACEUTICAL COMPOSITIONS
AU2016283517A AU2016283517B2 (en) 2015-06-22 2016-05-27 Ophthalmic formulations of tyrosine kinase inhibitors, methods of use thereof, and preparation methods thereof
CA2989121A CA2989121C (en) 2015-06-22 2016-05-27 Ophthalmic formulations of tyrosine kinase inhibitors, methods of use thereof, and preparation methods thereof
CN201680029483.5A CN107708664B (en) 2015-06-22 2016-05-27 Ophthalmic formulations of tyrosine kinase inhibitors, methods of use thereof, and methods of making the same
JP2017566347A JP6680807B2 (en) 2015-06-22 2016-05-27 Ophthalmic formulation of tyrosine kinase inhibitor, pharmaceutical composition, and pterygium and pharmaceutical composition for treating symptoms thereof
US15/700,735 US10154994B2 (en) 2015-06-22 2017-09-11 Ophthalmic formulations of tyrosine kinase inhibitors, methods of use thereof, and preparation methods thereof
US15/964,235 US11369600B2 (en) 2015-06-22 2018-04-27 Ophthalmic formulations of tyrosine kinase inhibitors, methods of use thereof, and preparation methods thereof
US17/750,400 US20220280506A1 (en) 2015-06-22 2022-05-23 Ophthalmic formulations of tyrosine kinase inhibitors, methods of use thereof, and preparation methods thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562183180P 2015-06-22 2015-06-22
US62/183,180 2015-06-22

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/700,735 Continuation US10154994B2 (en) 2015-06-22 2017-09-11 Ophthalmic formulations of tyrosine kinase inhibitors, methods of use thereof, and preparation methods thereof

Publications (1)

Publication Number Publication Date
WO2016209555A1 true WO2016209555A1 (en) 2016-12-29

Family

ID=57586141

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/034822 WO2016209555A1 (en) 2015-06-22 2016-05-27 Ophthalmic formulations of tyrosine kinase inhibitors, methods of use thereof, and preparation methods thereof

Country Status (10)

Country Link
US (3) US10154994B2 (en)
EP (1) EP3310339A4 (en)
JP (1) JP6680807B2 (en)
KR (2) KR102096296B1 (en)
CN (1) CN107708664B (en)
AU (1) AU2016283517B2 (en)
CA (1) CA2989121C (en)
MX (1) MX2017016655A (en)
TW (2) TWI664965B (en)
WO (1) WO2016209555A1 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017210132A1 (en) 2016-06-02 2017-12-07 Cloudbreak Therapeutics, Llc Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularization
WO2018052053A1 (en) 2016-09-13 2018-03-22 協和発酵キリン株式会社 Medicinal composition
WO2018054077A1 (en) * 2016-09-26 2018-03-29 Reyoung (Suzhou) Biology Science & Technology Co., Ltd Composition for treating ocular diseases and methods of usage and making
US9980901B2 (en) 2015-06-06 2018-05-29 Cloudbreak Therapeutics, Llc Compositions and methods for treating pterygium
WO2018165865A1 (en) 2017-03-14 2018-09-20 新源生物科技股份有限公司 Crystal forms of 3-z-[1-(4-(n-((4-methyl-piperazin-1-yl)-methylcarbonyl)-n-methyl-amino)-phenylamino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone
US10154994B2 (en) 2015-06-22 2018-12-18 Allgenesis Biotherapeutics, Inc. Ophthalmic formulations of tyrosine kinase inhibitors, methods of use thereof, and preparation methods thereof
CN109996814A (en) * 2017-05-01 2019-07-09 艾葳控股有限公司 Multi-kinase inhibitor and the purposes in eye fibrosis
WO2019144060A1 (en) * 2018-01-19 2019-07-25 Aiviva Biopharma Inc. Suspension compositions of multi-target inhibitors
WO2020055713A1 (en) * 2018-09-10 2020-03-19 Taiwan Liposome Co., Ltd. Sustained-release ophthalmic pharmaceutical compositions and uses thereof
WO2020223177A1 (en) * 2019-04-29 2020-11-05 The Board Of Trustees Of The University Of Illinois Mek inhibitors for corneal scarring and neovascularization

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200237859A1 (en) 2019-01-25 2020-07-30 Newport Research, Inc. Aqueous suspensions of cyclosporin
US11324800B2 (en) 2015-01-15 2022-05-10 Wellspring Ophthalmics, Inc. Aqueous suspensions of cyclosporin
CN108295072A (en) * 2015-12-09 2018-07-20 瑞阳(苏州)生物科技有限公司 Nintedanib prevents the purposes of eye disease
IT201800005599A1 (en) * 2018-05-22 2019-11-22 Soft contact lens
CN110664757B (en) * 2018-11-19 2022-08-02 成都瑞沐生物医药科技有限公司 Nanocrystalline eye drop, preparation method and application thereof
US20200345805A1 (en) * 2019-04-22 2020-11-05 Allegro Ophthalmics, Llc Compositions and methods useable for treatment of dry eye
US20220331310A1 (en) * 2019-09-10 2022-10-20 Cloudbreak Therapeutics, Llc Methods for alleviating pterygium-associated worry about eye appearance
EP4171507A1 (en) * 2020-06-30 2023-05-03 Oculis SA Preparation of solid cyclodextrin complexes for ophthalmic active pharmaceutical ingredient delivery
US20240180846A1 (en) * 2021-06-08 2024-06-06 The United States Government As Represented By The Department Of Veterans Affairs Nanoformulations of Pazopanib, Compositions Comprising the Same and Methods of Treating Osteoarthritis
CN118119599A (en) * 2021-10-15 2024-05-31 视尔普斯眼科公司 Acetinib prodrugs
CN116251186A (en) * 2021-12-09 2023-06-13 成都瑞沐生物医药科技有限公司 Tyrosine kinase inhibitor ophthalmic preparation and preparation method and application thereof
WO2023235267A2 (en) * 2022-05-28 2023-12-07 Avalyn Pharma Inc. Nintedanib and nintedanib combination dry powder compositions and uses
KR20240028815A (en) 2022-08-25 2024-03-05 주식회사 스카이테라퓨틱스 A molecule aggregates composite of active pharmaceutical ingredient and a pharmaceutical composition comprising the same
WO2024064848A2 (en) * 2022-09-23 2024-03-28 Inoculus Ventures, Inc. Dry eye treatment
WO2024081410A1 (en) * 2022-10-14 2024-04-18 Ocular Therapeutix, Inc. Prodrugs, formulations and methods thereof

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110142923A1 (en) 2008-08-08 2011-06-16 Maria Grazia Mazzone Ophthalmic pharmaceutical compositions for the treatment of neoangiogenic pathologies of the eye
US20130316006A1 (en) 2012-05-03 2013-11-28 Kala Pharmaceuticals, Inc. Particles, compositions and methods for ophthalmic and/or other applications
WO2014074823A1 (en) 2012-11-08 2014-05-15 Clearside Biomedical, Inc. Methods and devices for the treatment of ocular diseases in human subjects
US20140235678A1 (en) 2011-06-28 2014-08-21 Bayer Healthcare Llc Topical Ophthalmological Pharmaceutical Composition containing Sorafenib
US20150037422A1 (en) 2012-02-22 2015-02-05 Trustees Of Tufts College Compositions and methods for ocular delivery of a therapeutic agent
US20150141448A1 (en) 2012-06-25 2015-05-21 Bayer Healthcare Llc Topical Ophthalmological Pharmaceutical Composition containing Pazopanib
US20150164790A1 (en) 2012-06-12 2015-06-18 Bayer Healthcare Llc Topical Ophthalmological Pharmaceutical Composition containing Axitinib
WO2016200688A1 (en) 2015-06-06 2016-12-15 Cloudbreak Therapeutics, Llc Compositions and methods for treating pterygium

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6071904A (en) * 1996-12-11 2000-06-06 Alcon Laboratories, Inc. Process for manufacturing ophthalmic suspensions
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
US20080003219A1 (en) 2005-09-26 2008-01-03 Minu, L.L.C. Delivery of an ocular agent
WO2007038453A2 (en) 2005-09-26 2007-04-05 Advanced Ocular Systems Limited Use of an anti-vascular endothelial growth factor (vegf) agent to ameliorate inflammation
JP2009543797A (en) * 2006-07-10 2009-12-10 エラン ファーマ インターナショナル，リミティド Nanoparticulate sorafenib formulation
RU2351298C1 (en) 2007-11-27 2009-04-10 Государственное учреждение "УФИМСКИЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ИНСТИТУТ ГЛАЗНЫХ БОЛЕЗНЕЙ" Академии наук Республики Башкортостан (УфНИИ ГБ АН РБ) Method of prevention of pterygium relapse
EP2181991A1 (en) 2008-10-28 2010-05-05 LEK Pharmaceuticals D.D. Novel salts of sunitinib
US20100226992A1 (en) * 2009-03-03 2010-09-09 Alcon Research, Ltd. Pharmaceutical Composition for Delivery of Receptor Tyrosine Kinase Inhibiting (RTKi) Compounds to the Eye
BRPI1015356A2 (en) * 2009-06-30 2016-05-10 Allergan Inc liquid ophthalmic pharmaceutical compositions containing propionic acid derivatives as a preservative.
JP2017512748A (en) 2012-06-25 2017-05-25 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ Ophthalmic topical pharmaceutical composition containing sunitinib
US8747852B1 (en) 2012-12-28 2014-06-10 Randal Tanh Hoang Pham Methods of treating pterygium
US20160038760A1 (en) 2013-03-14 2016-02-11 Massachusetts Eye And Ear Infirmary Conjunctival diseases
TWI664965B (en) 2015-06-22 2019-07-11 新源生物科技股份有限公司 Ophthalmic formulations of tyrosine kinase inhibitors, methods of use thereof, and preparation methods thereof

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110142923A1 (en) 2008-08-08 2011-06-16 Maria Grazia Mazzone Ophthalmic pharmaceutical compositions for the treatment of neoangiogenic pathologies of the eye
US20140235678A1 (en) 2011-06-28 2014-08-21 Bayer Healthcare Llc Topical Ophthalmological Pharmaceutical Composition containing Sorafenib
US20150037422A1 (en) 2012-02-22 2015-02-05 Trustees Of Tufts College Compositions and methods for ocular delivery of a therapeutic agent
US20130316006A1 (en) 2012-05-03 2013-11-28 Kala Pharmaceuticals, Inc. Particles, compositions and methods for ophthalmic and/or other applications
US20150164790A1 (en) 2012-06-12 2015-06-18 Bayer Healthcare Llc Topical Ophthalmological Pharmaceutical Composition containing Axitinib
US20150141448A1 (en) 2012-06-25 2015-05-21 Bayer Healthcare Llc Topical Ophthalmological Pharmaceutical Composition containing Pazopanib
WO2014074823A1 (en) 2012-11-08 2014-05-15 Clearside Biomedical, Inc. Methods and devices for the treatment of ocular diseases in human subjects
WO2016200688A1 (en) 2015-06-06 2016-12-15 Cloudbreak Therapeutics, Llc Compositions and methods for treating pterygium

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BERGE ET AL., J. PHARM. SCI., vol. 66, 1977, pages 1 - 19
CAMPOS-MOLLO ET AL.: "New Corneal Neovascularization Model in Rabbits for Angiogenesis Research", OPHTHALMIC RES, vol. 45, 2010, pages 135 - 141
HUU ET AL.: "light-responsive nanoparticle depot to control release of a small molecule angiogenesis inhibitor in the posterior segment of the eye", JOURNAL OF CONTROL RELEASE, vol. 200, 5 January 2015 (2015-01-05), pages 71 - 7, XP029222017, DOI: 10.1016/j.jconrel.2015.01.001
M BAROT ET AL.: "ProDrug Strategies in Ocular Drug Delivery", MED CHEM, vol. 8, no. 4, 2012, pages 753 - 768, XP055944741, DOI: 10.2174/157340612801216283
RAUTIO ET AL., NATURE REVIEWS, vol. 7, 2008, pages 255 - 270
See also references of EP3310339A4
SEO ET AL.: "Inhibition of Corneal Neovascularization in Rats by Systemic Administration of Sorafenib", CORNEA, vol. 31, no. 8, 2012, pages 907, XP055788614, DOI: 10.1097/ICO.0b013e31823f8b9c
WOLLIN ET AL.: "Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis", EUROPEAN RESPIRATORY JOURNAL, vol. 45, 1 May 2015 (2015-05-01), pages 1434 - 1445, XP055341429, DOI: 10.1183/09031936.00174914
WOLLIN, L ET AL.: "Mode of Action of Nintedanib in the Treatment of Idiopathic Pulmonary Fibrosis.", EURPOEAN RESPIRATORY JOURNAL., vol. 45, no. 5, 5 March 2015 (2015-03-05), pages 1435 - 1445, XP055341429 *

Cited By (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10149819B2 (en) 2015-06-06 2018-12-11 Cloudbreak Therapeutics, Llc Compositions and methods for treating hyperemia
US10980741B2 (en) 2015-06-06 2021-04-20 Cloudbreak Therapeutics, Llc Compositions and methods for treating pterygium recurrence
EP3302379B1 (en) * 2015-06-06 2023-11-22 Cloudbreak Therapeutics, LLC Compositions and methods for treating pterygium
US9980901B2 (en) 2015-06-06 2018-05-29 Cloudbreak Therapeutics, Llc Compositions and methods for treating pterygium
US9987223B2 (en) 2015-06-06 2018-06-05 Cloudbreak Therapeutics, Llc Compositions and methods for treating pterygium
US10149820B2 (en) 2015-06-06 2018-12-11 Cloudbreak Therapeutics, Llc Compositions and methods for treating pterygium
US11369600B2 (en) 2015-06-22 2022-06-28 Allgenesis Biotherapeutics Inc. Ophthalmic formulations of tyrosine kinase inhibitors, methods of use thereof, and preparation methods thereof
US10154994B2 (en) 2015-06-22 2018-12-18 Allgenesis Biotherapeutics, Inc. Ophthalmic formulations of tyrosine kinase inhibitors, methods of use thereof, and preparation methods thereof
EP3463315A4 (en) * 2016-06-02 2020-01-15 Cloudbreak Therapeutics, LLC Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularization
US11246864B2 (en) 2016-06-02 2022-02-15 Ads Therapeutics Llc Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularization
AU2017274197B2 (en) * 2016-06-02 2022-02-10 Ads Therapeutics Llc Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularization
WO2017210132A1 (en) 2016-06-02 2017-12-07 Cloudbreak Therapeutics, Llc Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularization
US10688092B2 (en) 2016-06-02 2020-06-23 Cloudbreak Therapeutics, Llc Compositions and methods of using nintedanib for improving glaucoma surgery success
EP4248971A3 (en) * 2016-06-02 2024-02-14 ADS Therapeutics LLC Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularization
US11911379B2 (en) 2016-06-02 2024-02-27 Ads Therapeutics Llc Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularization
US11278546B2 (en) 2016-07-22 2022-03-22 Aiviva Biopharma, Inc. Multikinase inhibitors and uses in ocular fibrosis
WO2018052053A1 (en) 2016-09-13 2018-03-22 協和発酵キリン株式会社 Medicinal composition
US10894043B2 (en) 2016-09-13 2021-01-19 Kyowa Kirin Co., Ltd. Pharmaceutical composition
KR20190050794A (en) 2016-09-13 2019-05-13 교와 핫꼬 기린 가부시키가이샤 Medicinal composition
US11951103B2 (en) 2016-09-13 2024-04-09 Kyowa Kirin Co., Ltd. Pharmaceutical composition
EA038692B1 (en) * 2016-09-13 2021-10-05 Киова Кирин Ко., Лтд. Pharmaceutical composition
EP4000634A1 (en) 2016-09-13 2022-05-25 Kyowa Kirin Co., Ltd. Medicinal composition comprising tivozanib
CN107865821A (en) * 2016-09-26 2018-04-03 瑞阳(苏州)生物科技有限公司 A kind of preparation for preventing or treating CNV and formed
WO2018054077A1 (en) * 2016-09-26 2018-03-29 Reyoung (Suzhou) Biology Science & Technology Co., Ltd Composition for treating ocular diseases and methods of usage and making
US10772885B2 (en) * 2016-09-26 2020-09-15 Reyoung (Suzhou) Biology Science & Technology Co., Ltd. Composition for treating ocular diseases and methods of usage and making
US20190224194A1 (en) * 2016-09-26 2019-07-25 Reyoung (Suzhou) Biology Science & Technology Co., Ltd. Composition for treating ocular diseases and methods of usage and making
CN116063221A (en) * 2017-03-14 2023-05-05 新源生物科技股份有限公司 Crystalline forms of nildanib
JP7306697B2 (en) 2017-03-14 2023-07-11 オールジェネシス バイオセラピューティクス インコーポレイテッド 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-phenylamino)-1-phenyl-methylene]-6- Crystal form of methoxycarbonyl-2-indolinone
US10961203B2 (en) 2017-03-14 2021-03-30 Allgenesis Biotherapeutics Inc. Crystalline forms of 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-phenylamino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone
WO2018165865A1 (en) 2017-03-14 2018-09-20 新源生物科技股份有限公司 Crystal forms of 3-z-[1-(4-(n-((4-methyl-piperazin-1-yl)-methylcarbonyl)-n-methyl-amino)-phenylamino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone
CN110072849A (en) * 2017-03-14 2019-07-30 新源生物科技股份有限公司 The crystal form of 3-Z- [1- (4- (N- ((4- thyl-piperazin -1- base)-first carbonyl)-N- Methyl-amino)-phenylamino) -1- phenyi-methylene] -6- methoxycarbonyl group -2- dihydroindole ketone
JP2021176899A (en) * 2017-03-14 2021-11-11 オールジェネシス バイオセラピューティクス インコーポレイテッド Crystal form of 3-z-[1-(4 -(n-(4-methyl-piperazine-1-yl)- methylcarbonyl)-n-methyl-amino)- phenylamino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone
JP2020508979A (en) * 2017-03-14 2020-03-26 オールジェネシス バイオセラピューティクス インコーポレイテッド 3-Z- [1- (4- (N-((4-methyl-piperazin-1-yl) -methylcarbonyl) -N-methyl-amino) -phenylamino) -1-phenyl-methylene] -6 Crystal form of methoxycarbonyl-2-indolinone
CN109996814A (en) * 2017-05-01 2019-07-09 艾葳控股有限公司 Multi-kinase inhibitor and the purposes in eye fibrosis
EP3619232A4 (en) * 2017-05-01 2021-01-13 AiViva Biopharma, Inc. Multikinase inhibitors and uses in ocular fibrosis
CN109996814B (en) * 2017-05-01 2023-08-11 艾葳生物科技有限公司 Multi-kinase inhibitors and their use in ocular fibrosis
JP2019524880A (en) * 2017-05-01 2019-09-05 アイビバ バイオファーマ インコーポレイテッド Multikinase inhibitor
EP3740202A4 (en) * 2018-01-19 2021-12-15 AiViva Biopharma, Inc. Suspension compositions of multi-target inhibitors
AU2019208350B2 (en) * 2018-01-19 2022-05-26 Aiviva Biopharma, Inc. Suspension compositions of multi-target inhibitors
JP2021511323A (en) * 2018-01-19 2021-05-06 アイビバ バイオファーマ インコーポレイテッド Suspension composition of multi-target inhibitor
CN111741749A (en) * 2018-01-19 2020-10-02 艾葳生物科技有限公司 Suspension composition of multi-target inhibitor
WO2019144060A1 (en) * 2018-01-19 2019-07-25 Aiviva Biopharma Inc. Suspension compositions of multi-target inhibitors
US20210275447A1 (en) * 2018-09-10 2021-09-09 Taiwan Liposome Co., Ltd. Sustained-release ophthalmic pharmaceutical compositions and uses thereof
WO2020055713A1 (en) * 2018-09-10 2020-03-19 Taiwan Liposome Co., Ltd. Sustained-release ophthalmic pharmaceutical compositions and uses thereof
WO2020223177A1 (en) * 2019-04-29 2020-11-05 The Board Of Trustees Of The University Of Illinois Mek inhibitors for corneal scarring and neovascularization

Also Published As

Publication number Publication date
AU2016283517B2 (en) 2019-01-03
US10154994B2 (en) 2018-12-18
TW201703770A (en) 2017-02-01
US20220280506A1 (en) 2022-09-08
KR102096296B1 (en) 2020-04-06
CN107708664A (en) 2018-02-16
TWI700085B (en) 2020-08-01
MX2017016655A (en) 2018-05-15
TWI664965B (en) 2019-07-11
EP3310339A1 (en) 2018-04-25
CA2989121A1 (en) 2016-12-29
US20170368061A1 (en) 2017-12-28
BR112017025757A2 (en) 2018-08-14
EP3310339A4 (en) 2019-06-19
CN107708664B (en) 2021-10-19
US11369600B2 (en) 2022-06-28
AU2016283517A1 (en) 2017-12-14
KR20200018714A (en) 2020-02-19
CA2989121C (en) 2022-09-27
JP6680807B2 (en) 2020-04-15
KR20170140399A (en) 2017-12-20
US20180243294A1 (en) 2018-08-30
JP2018524327A (en) 2018-08-30
TW201936187A (en) 2019-09-16

Similar Documents

Publication Publication Date Title
US20220280506A1 (en) Ophthalmic formulations of tyrosine kinase inhibitors, methods of use thereof, and preparation methods thereof
US8492334B2 (en) Sustained intraocular delivery of drugs from biodegradable polymeric microparticles
TWI752083B (en) Pharmaceutical composition
Hippalgaonkar et al. Indomethacin-loaded solid lipid nanoparticles for ocular delivery: development, characterization, and in vitro evaluation
Ibrahim et al. Natural bioadhesive biodegradable nanoparticle-based topical ophthalmic formulations for management of glaucoma
US20190070176A1 (en) Method of increasing bioavailability and/or prolonging ophthalmic action of a drug
CN106061261B (en) Crystal form of therapeutic compounds and application thereof
US20160101054A1 (en) Sustained delivery of drugs from biodegradable polymeric microparticles
US20030185892A1 (en) Intraocular delivery compositions and methods
KR20150006869A (en) Pharmaceutical nanoparticles showing improved mucosal transport
JP7026609B2 (en) Fine particle-containing composition and its manufacturing method
US20110123622A1 (en) Ophthalmic formulation and method of manufacture thereof
JP6426195B2 (en) Crystalline forms of therapeutic compounds and uses thereof
Fang et al. Vesicular phospholipid gels as topical ocular delivery system for treatment of anterior uveitis
TWI707684B (en) Ophthalmic suspension preparation
More et al. Review on solid lipid nanoparticles for ophthalmic delivery
BR112017025757B1 (en) OPHTHALMIC FORMULATIONS OF TYROSINE KINASE INHIBITORS AND THEIR PHARMACEUTICAL COMPOSITIONS
Acharya Development and Evaluation of Liquid Crystalline Cubogel for Ocular Delivery of Anti-glaucoma Agents
Omerović et al. Evaluation of Targeted Nanoparticles for Ocular Delivery
EP1366758A1 (en) Novel ophthalmic compositions

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16814997

Country of ref document: EP

Kind code of ref document: A1

REEP Request for entry into the european phase

Ref document number: 2016814997

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20177034479

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2989121

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2016283517

Country of ref document: AU

Date of ref document: 20160527

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 11201710320U

Country of ref document: SG

WWE Wipo information: entry into national phase

Ref document number: MX/A/2017/016655

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2017566347

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112017025757

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112017025757

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20171130